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CYCLIN B1 MEDIATES THE EFFECT OF UCHL1 IN PROMOTING CELL CYCLE
PROGRESSION IN UTERINE PAPILLARY SEROUS CARCINOMA

Suet Ying Kwan, BSc
Advisory Professor: Karen H. Lu, M.D.

Uterine papillary serous carcinoma (UPSC) is an aggressive form of endometrial cancer with
poor survival rates and a high risk of recurrence. The rarity of UPSC poses challenges to the
discovery of novel targeted therapies. Therefore, the purpose of this dissertation was to identify novel
therapeutic targets that could aid in the management of UPSC. To do so, we began with the relatively
large cohort of UPSC cases in the TCGA data set, which was used to identify differentially expressed
genes between UPSC and low-grade endometrioid endometrial carcinoma (EEC) and normal tissue.
We identified Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) to be a gene of interest,
as it was significantly upregulated in UPSC and correlated with poorer overall survival. These
findings were validated through immunohistochemical analysis of an independent cohort of tumor
samples. Due to its role as a deubiquitinating enzyme, we hypothesized that UCHL1 contributes to
UPSC tumor progression by modulating the protein stability of target genes.
To test this hypothesis, we first examined the functional role of UCHL1 in UPSC
progression. Subsequently, we found that UCHL1 silencing reduced cell proliferation in vitro and in
vivo. The treatment of UPSC-bearing mice with the UCHL1-specific inhibitor LDN-57444 via
intraperitoneal injection also reduced tumor growth and increased overall survival times.
Next, we found that the effect of UCHL1 on increased cell proliferation was due to its ability
to stabilize cyclin B1 protein, an essential protein in mitotic progression. Specifically, we
demonstrated that UCHL1 and cyclin B1 interact with each other in both the cytoplasm and nuclear
space prior to mitosis. UCHL1 silencing increased the deubiquitination of cyclin B1, suggesting that
UCHL1 counteracts the ubiquitination of cyclin B1 by the anaphase-promoting complex.
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Accordingly, UCHL1 silencing slowed the progression of cells into mitosis. Taken together, our
findings indicate that UCHL1 impairs the degradation of cyclin B1, leading to uncontrolled cell cycle
progression. In summary, we have identified UCHL1 as a prognostic marker for UPSC and a viable
therapeutic target.
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CHAPTER 1:
INTRODUCTION
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ENDOMETRIAL CANCER
Endometrial cancer (EC) is the most common gynecologic malignancy in the United States. It
is estimated that there will be 61,380 new cases and 10,920 deaths in the United States alone in 2017
[1]. Worldwide incidence of EC is steadily rising, with an average annual increase of 2.0% from 2008
to 2011 in the Unites States [2]. This increase is predicted to continue through the next few decades,
with 122,000 expected number of cases in the Unites States by 2030 [3]. In spite of this, overall 5year survival rates have not improved (87% from 1975 to 1977 versus 83% from 2005 to 2011) [2].
The increase in endometrial cancer incidence is attributed to multiple factors. For example,
endometrial cancer risk is strongly associated with obesity [4], which is on the rise worldwide [5, 6].
Obesity leads to an imbalance in estrogen/progesterone levels; unopposed excess estrogen and
insufficient progesterone is the primary risk factor for the majority of endometrial cancers [7].
Obesity is also linked to other hormonal abnormalities such as hyperinsulinemia, which further
increase the risk of endometrial cancer. Other factors contributing to increasing incidence are the
advancing age of the population, and a decrease in hormone therapy for menopausal women that
counteracts estrogen to relieve symptoms [8].

Histopathological classification of endometrial cancer
Endometrial cancers are categorized into two subtypes based on their histopathology [9].
Type I malignancies comprise approximately 80% of all endometrial cancer cases and are
characterized by endometrioid histologic features, low histological grade, limited myometrial spread,
and an overall favorable prognosis. In contrast, type II malignancies, which include grade 3
endometrioid carcinoma, uterine papillary serous carcinoma (UPSC) and clear cell carcinoma, are
associated with presentation at an older age and a poorer prognosis.
UPSC is the most common non-endometrioid endometrial carcinoma and the most aggressive
type II variant: although comprising less than 10% of all endometrial cancers, it accounts for
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approximately 40% of deaths [10, 11]. Poor survival outcome is partly due to the high percentage of
cases diagnosed at stage III and VI (41.3% as opposed to 13.9% of EEC) [12]. While the risk of
metastasis and recurrence in type I cancers can be predicted from the tumor size, grade, and depth of
myometrial invasion [13-16], such factors are not predictive for UPSC [17-19]. Disease stage and the
presence of extra-uterine disease are risk factors for overall survival [20, 21], but both early- and latestage UPSC behave aggressively and show a tendency towards lymphovascular invasion,
intraperitoneal disease and extra-abdominal spread [22-24].

Pathogenesis of endometrial cancer
The pathogenesis of EEC has been well characterized (Figure 1). Positive estrogen or
progestin receptor status is common, and patients present at a relatively young age. Unopposed
estrogen stimulation and an early loss of the tumor suppressor PTEN give rise to complex atypical
hyperplasia, the precursor to most type I carcinomas [25-27]. Mutations in CTNNB1 and KRAS, as
well as microsatellite instability arising from defects in DNA mismatch repair, are common additional
features [28-30].
In contrast, patients with UPSC present at an older age, and the majority are postmenopausal
[31]; therefore, these tumors frequently arise from a background of atrophic endometrium [32, 33]
and the majority are estrogen and/or progesterone receptor-negative [34]. Endometrial glandular
dysplasia (EmGD) has been described as the putative precancerous lesion [35, 36], with an
intermediate level of morphological atypia between normal endometrium and UPSC [37], followed
by the development of minimally invasive endometrial intraepithelial carcinoma (EIC), characterized
by cells closely resembling UPSC but confined to the surface endometrium [38]. Histological studies
have observed frequent co-occurrence of EmGD and EIC with UPSC [20, 21, 32, 39].
TP53 mutation occurs early in carcinogenesis – approximately 80%-90% of UPSCs carry a
mutation [40-42]. While type I tumors tend to be diploid, aneuploidy is observed in the majority of
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UPSC cases [43, 44]. HER2/neu amplification or overexpression has been reported in 15% to 62% of
UPSC cases and is correlated with advanced stage and poorer progression-free and overall survival
[45-52]. There is also frequent loss of the cell adhesion molecule E-cadherin [53, 54] and
upregulation of the tight junction proteins claudin-3 and -4 [55], which may explain the enhanced
ability of UPSC tumor cells to detach from the primary tumor. The cell cycle-related proteins, p16
and cyclin E1, are also overexpressed [42, 56-59].
It has been suggested that a minority of non-endometrioid carcinomas can also arise from
dedifferentiation of high grade endometrioid carcinomas, due to microsatellite instability and
accumulation of mutations such as TP53 [60-62]. This would explain the frequent presentation of
mixed endometrioid and serous histology, and why mixed cases more commonly present in a
background of hyperplastic endometrium, while pure serous carcinomas present more in atrophic or
weakly proliferative endometrium [33, 63]. Further studies are needed to establish this possible
alternative pathogenesis.
Several independent studies have compared the survival outcomes of grade 3 EEC and
UPSC, with some finding equally poor survival between the two for both early- and late-stage
patients [64, 65], while others have observed poorer survival in UPSC [66-69]. Of these, the largest
study of 2316 grade 3 EEC and 1473 UPSC patients indicated a statistically significant difference in
survival at each stage [68], suggesting that grade 3 endometrioid carcinomas is of intermediate risk
between grade 1 and 2 endometrioid carcinomas and non-endometrioid carcinomas.
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Figure 1. Molecular pathogenesis of endometrioid and serous endometrial cancer.

Molecular classification of endometrial cancer
Classification of endometrial cancer based on histology and cell morphology is unreliable for
high-grade tumors, and EEC tumors can be misdiagnosed as papillary serous and vice versa,
especially when an ECC tumor displays villoglandular morphology [70, 71]. Therefore, extra criteria
for determining risk would improve reliability.
The Nature paper published by the TCGA network on endometrial cancer [72] suggested
categorizing endometrial tumors into four novel groups, based on integrated mutational analysis using
exome sequencing, copy number alterations, and microsatellite instability (MSI) status of 248
tumor/normal sample pairs: i) POLE ultramutated; ii) MSI-high hypermutated; iii) copy-number low
(endometrioid); and iv) copy-number high (serous-like). Unsupervised clustering of multiplatform
data (RNA, protein, microRNA expression and DNA methylation) was reported to correlate well with
5

these four groups. Overall survival outcomes were different between the groups: the POLE
ultramutated group exhibited the best prognosis for progression-free survival, while the copy-number
high group had the worst prognosis. In accordance with previously established data, the majority of
UPSC cases were in the copy-number high group, along with a quarter of all grade 3 EEC. Tumors in
this group were characterized by a high number of somatic copy number alterations, as well as a low
mutation rate and high frequency of TP53 mutation. Only two serous cases (pure or mixed) were not
in this group, one of which underwent histological re-review based on its TP53 wild-type status,
KRAS mutation and high mutation rate, and was subsequently reclassified as grade 3 EEC.
The endometrial tumors were also clustered by individual data sets (mRNA expression,
protein expression, miRNA expression and DNA methylation). These results further indicated that a
subset of grade 3 EEC are molecularly similar to UPSC, and also revealed that these serous/serouslike tumors have frequent dysregulation of cell cycle proteins, particularly those involved in mitosis.
Of note, unsupervised clustering of mRNA profiles identified mitotic, hormonal and immunoreactive
clusters. 92% of pure/mixed UPSC tumors and 56% of grade 3 EEC were in the mitotic cluster,
characterized by dysregulation of cell cycle genes such as CCNB2 and CDK1, as well as TP53
mutation. Furthermore, supervised analysis of reverse phase protein array (RPPA) profiles showed
that the mitotic cluster had high protein expression of cyclin B1, cyclin E1 and CDK1.

UPSC patterns of spread
The UPSC precursor, endometrial intraepithelial carcinoma (EIC), is characterized by the
transformation of atrophic surface epithelium and underlying glands into malignant cells. These cells
exhibit anaplastic nuclei and morphology resembling invasive UPSC, but stromal or myometrial
invasion is absent [32]. In spite of this, EIC may still be associated with extra-uterine tumor: a study
of 40 EIC or UPSC with invasion limited to the endometrium found presence of extra-uterine disease
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in 45% of cases [73], while another found extra-uterine disease in 6 out of 9 patients with EIC [74],
highlighting the need for complete surgical staging.
As the risk of extra-uterine disease is predicted by depth of myometrial invasion in EEC but
not in UPSC, it indicates that the two subtypes have distinct mechanisms of spread. While EEC
tumors commonly reach the peritoneal cavity by invasion through the myometrium, UPSC tumors are
more likely to metastasize via the lymphatic/vascular system [18]. One additional mechanism of
spread for UPSC is the retrograde passage of exfoliated tumor cells through the fallopian tubes and
subsequent dissemination into the peritoneal cavity. In one study of patients with extra-uterine
disease, 48% did not have lymphatic/vascular disease and 33% did not have myometrial invasion
[75]. Ayeni et al. [76] also observed a significantly lower frequency of positive peritoneal cytology in
patients with tubal ligation versus those without (18.8% versus 45%), along with an improved overall
survival rate in late stage patients with tubal ligation. However, positive peritoneal cytology was not
completely eradicated, indicating that EIC and UPSC can utilize one of several methods of spread to
reach the peritoneal cavity.

Current treatment strategies for endometrial cancer
Current treatment for endometrial cancer varies according to stage of disease and histological
type. Complete surgical staging is recommended for all tumor types, comprising total hysterectomy,
bilateral salpingo-oophorectomy and lymph node dissection [77]. Omentectomy and peritoneal
washings are also performed, especially in patients with UPSC. Optimal cytoreduction (≤ 1 cm
maximum diameter of residual tumor nodules) has been shown to increase median overall survival in
both early and late stage UPSC patients [78]. In one study of 79 patients with late stage UPSC, the
median overall survival time was 39 months for patients with optimal cytoreduction, which was
significantly higher than the 12 month survival time of patients with suboptimal cytoreduction [79].
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In addition, since stage and presence of extra-uterine disease are the main prognostic factors,
complete surgical staging has prognostic benefit.
Following cytoreductive surgery, adjuvant chemotherapy and radiation therapy is considered
for patients with endometrial cancer [80]. Carboplatin and paclitaxel is considered the optimal
chemotherapy regimen [81, 82]. Adjuvant chemotherapy has not been proven to improve outcomes
for patients with early stage EEC; adjuvant radiation may reduce the risk of local recurrence but does
not improve overall survival. Therefore, only 28% of patients with stage I and II disease received
adjuvant chemotherapy and/or radiation treatment in 2013 [83]. In contrast, 66% of patients with late
stage EEC received adjuvant therapy. Chemotherapy improves outcomes for patients with late-stage
EEC and is considered the optimal chemotherapy regimen; the addition of radiation therapy confers
additional benefit.
If any UPSC component is present in the tumor, patients are considered high risk regardless
of presence of extrauterine disease and are therefore recommended for adjuvant therapy. After
cytoreductive surgery, adjuvant chemotherapy appears to confer a survival advantage in both early
and late-stage UPSC, while the benefit of adjuvant radiotherapy has yet to be established [10, 78].
With current therapy, the 5-year disease-specific survival for UPSC is approximately 74%
and 33% for early-stage and late-stage patients [68, 84], compared to 77% in grade 3 EEC and 89% in
low-grade EEC [85]. In light of the poor patient survival rates and high recurrence rates, the
development of targeted therapies specific to UPSC pathway aberrations would likely aid in its
management [10, 17, 78].

Development of targeted therapeutic strategies for UPSC
Several targets are being investigated for UPSC treatment. For example, due to the frequent
amplification and overexpression of HER2/neu in UPSC and other cancers, various anti-HER2
therapies have been developed. The first developed anti-HER2 monoclonal antibody, trastuzumab,
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recruits natural killer cells to tumor cells and initiates antibody-dependent cell-mediated cytotoxicity,
leading to cell cycle arrest and reduced angiogenesis [86, 87]. Its use has been FDA-approved for
HER2-positive breast cancer in combination with chemotherapy, where risk of death in patients with
metastatic disease was reduced by 20% in a phase III trial. The EGFR and HER2 small molecule
inhibitor, afatinib, has also been FDA-approved as first-line treatment of metastatic non-small cell
lung cancer with activating EGFR mutations [88, 89], and as second-line treatment for advanced
squamous cell carcinoma of the lung that has progressed after platinum-based chemotherapy [90, 91].
Several clinical trials are investigating the benefit of using HER2 inhibitors in endometrial
cancer. Afatinib is being investigated in a phase II study (NCT02491099 [92]) for persistent or
recurrent UPSC confirmed to have HER2/neu overexpression. A GOG phase II study (GOG-181B
[93]) tested the use of trastuzumab as a single agent in advanced or recurrent HER2-positive
endometrial carcinoma. No significant activity was observed; however, only 33 patients were accrued
for the trial. Of these, only a third had UPSC histology, and HER2/neu amplification was only
confirmed in 55.5% of patients [94]. A current phase II study (NCT01367002 [95]) is investigating
the use of carboplatin and paclitaxel with or without trastuzumab in patients with advanced or
recurrent UPSC confirmed to have HER2 overexpression through IHC or fluorescence in situ
hybridization.
The differences in initial clinical response to trastuzumab observed in clinical trials with
endometrial cancer compared to breast cancer may be explained by a significantly higher frequency
of expression of the p95HER2 mutant in UPSC and grade 3 EEC than in breast cancer cases [96].
This truncated form of the protein lacks the trastuzumab-binding extracellular domain; subsequently,
its expression has been associated with trastuzumab resistance and poor progression-free and overall
survival in breast cancer [97, 98].
As the PIK3CA/AKT/mTOR pathway is downstream of HER2 and PIK3CA
mutation/amplification has been observed in almost half of all UPSC cases [42], several phase I and II
clinical trials are ongoing to evaluate the use of PI3KCA, AKT, and mTOR inhibitors in HER2/neu-
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amplified UPSC [99]. Concurrent inhibition of this pathway may reduce the resistance to HER2targeted therapies [100].
The pro-angiogenic vascular endothelial growth factor (VEGF) has been associated with
increasing grade, lymphovascular invasion and spread, and p53 upregulation in endometrial cancer
[101, 102]. A previous phase II study (GOG-229E [103]) investigated the use of Bevacizumab, the
monoclonal antibody against all isoforms of VEGF, in recurrent endometrial cancer. 27% of the
patients had UPSC tumors. A 13.5% clinical response rate was observed following 3 weeks of
treatment: 100% and 50% of those with complete and partial response were patients with UPSC.
Currently, another phase II study (NCT00513786 [104]) is evaluating the benefit of Bevacizumab in
combination with carboplatin and paclitaxel in advanced endometrial cancer.

THE UBIQUITIN-PROTEASOME SYSTEM
The ubiquitin-proteasome system is the major intracellular pathway through which normal
and misfolded/damaged proteins are degraded. Proteins are marked for degradation by the tagging of
ubiquitin, a highly conserved 76 amino-acid polypeptide; substrate proteins are then recognized by
the 26S proteasome. The process of ubiquitin conjugation to substrates is facilitated by the sequential
activity of three major classes of enzymes. Ubiquitin-activating enzymes (E1) activate ubiquitin in an
ATP-dependent process before transferring it to ubiquitin-conjugating enzymes (E2). Ubiquitinprotein ligases (E3) recognize substrate proteins both normal and damaged, and catalyzes the transfer
of activated ubiquitin from the E2 enzyme to a lysine residue or N-terminal amino acid of the target
protein [105-107].
Ubiquitin can be conjugated as a monomer or form polyubiquitin chains; all seven lysine
residues in the ubiquitin protein can be conjugated to additional ubiquitin molecules, forming
different polyubiquitin chains that lead to distinct downstream effects [108]. A chain of four or more
ubiquitin proteins linked via lysine 48 (K48-linked ubiquitination) is the canonical signal for
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degradation by the 26S proteasome. In addition to polyubiquitination, proteins can also be conjugated
to a single ubiquitin (monoubiquitination) or be conjugated to multiple ubiquitin monomers at
different sites within the protein (multi-monoubiquitination) [109].
As the conjugation of ubiquitin is reversible, ubiquitin can be removed from substrates, or
processed from ubiquitin chains back to monomers by deubiquitinating enzymes (DUBs). In addition,
small ubiquitin adducts form during the ubiquitination and proteolytic process, which must be
processed by DUBs for free ubiquitin monomers to be regenerated [110]. At least 98 DUBs exist,
which are classified into six groups [111].

UCHL1
UCHL1 is a DUB in the family of ubiquitin carboxyl-terminal hydrolases [112]. The most
understood function of UCHL1 in normal tissue is what characterizes members of its protein family:
the enzyme acts specifically on ubiquitin adducts, where its deubiquitinating activity catalyzes
hydrolysis at the C-terminal glycine of ubiquitin to generate ubiquitin monomers [113-115].
UCHL1 is one of the most abundant proteins in the brain, where it is localized to neurons and
ganglia. In rats, UCHL1 mRNA and protein was detected strongly in the brain and moderately in the
testis by northern blot and western blot analysis; expression was undetectable in the heart, lung,
pancreas, small intestine, liver, kidney, spleen and adrenal tissue [116]. In human, rat and guinea-pig
samples, protein expression as detected by polyclonal and monoclonal antibodies was restricted to the
central and peripheral nervous system, and in neuroendocrine cells. In addition, strong to moderate
immunohistochemical staining was observed in the germ cells and Leydig cells of the testis; in the
ova, theca externa and theca interna of the corpus luteum; and in the distal tubular epithelium and
calyceal urothelium [117]. UCHL1 protein was undetectable in the pancreas. Expression is
predominantly in the cytoplasm, with 5% of UCHL1-positive neuronal and neuroendocrine cells
displaying concurrent nuclear staining.
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Dysregulation of UCHL1 in cancer
The UCHL1 I93M mutation is associated with Parkinson’s disease [118, 119]. However,
mutations or amplification have not been reported in cancer; rather, UCHL1 expression is
dysregulated mainly by aberrant gene methylation in a multitude of cancer types. Hypermethylation
and/or loss of expression of UCHL1 has been reported in melanoma, colorectal, prostate, breast,
ovarian, nasopharyngeal and renal cancer [120-127]. On the other hand, UCHL1 hypomethylation
and/or overexpression has been observed in lymphoma, gallbladder, prostate, gastric and colorectal
cancer compared to normal tissue [128-132].
A long non-coding UCHL1 antisense RNA (UCHL1-AS1) has been identified, which initiates
transcription within the second intron of UCHL1 and overlaps with the beginning of the UCHL1 gene
[133]. UCHL1-AS1 increases UCHL1 protein levels by promoting translation of its mRNA. In mouse
tissue, UCHL1-AS1 was highly expressed in the ventral mid-brain and moderately expressed in the
colon, but expression was negative in other normal tissue samples, including the uterus.
Promotion of UCHL1 degradation by the E3-ubiquitin ligase, parkin (PARK2), has also been
reported. Parkin mediated the K63-linked ubiquitination of UCHL1 both in vitro and in mouse brain
extracts, leading to degradation through the autophagy-lysosome pathway [134]. The PARK2 gene is
frequently inactivated in various cancers through mutation, copy number loss, or promoter
hypermethylation [135]; however, its protein levels have not been studied in endometrial cancer.
Both oncogenic and tumor suppressive functions of UCHL1 have been described. Correlation
of high expression with worse clinical prognosis in melanoma, breast, lung, colorectal and pancreatic
ductal tumors suggests that UCHL1 contributes to tumorigenesis in these cancers [136-139]. In
addition, transgenic mice overexpressing UCHL1 under a ubiquitous promoter developed
spontaneous lipomas, lymphomas and lung adenomas [132]. Further studies in immortalized human
B-cell lines showed that UCHL1 promoted cell proliferation and survival. UCHL1 also promoted cell
invasion and motility in lung, colorectal and prostate cancer cells [140, 141]. Expression of wild-type
UCHL1, but not the catalytically inactive UCHL1 C90S mutant, induced epithelial-to-mesenchymal
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transition of normal prostatic epithelial cells [142], and UCHL1 silencing in a metastatic prostate
cancer cell line induced mesenchymal-to-epithelial transition.
Contrary to reports of UCHL1 overexpression, silencing of UCHL1 has also been reported in
breast carcinoma cell lines compared to normal breast tissue and mammary epithelial cells [143],
nasopharyngeal carcinoma cells [124], melanoma [120], and prostate cancer [127]. However, the role
of UCHL1 as a potential tumor suppressor has mostly been inferred from in vitro studies, rather than
by survival analysis of patient data. In vitro, reintroduction of UCHL1 suppressed colony formation
and proliferation through G0/G1 cell cycle arrest and apoptosis in breast carcinoma cell lines [143];
induced apoptosis in nasopharyngeal cell lines [124]; and reduced proliferation and anchorageindependent growth in prostate cancer cells [127].

Mechanisms of action of UCHL1
The mechanism through which UCHL1 contributes to tumorigenesis has not been fully
elucidated. As a deubiquitinating enzyme from the family of ubiquitin carboxyl-terminal hydrolases
[112], UCHL1 has been shown to affect the stability and/or activity of various cancer-related proteins
involved in cell cycle regulation, as well as cancer cell survival, metastasis and angiogenesis.

UCHL1 and cell cycle progression
UCHL1 is able to regulate cell cycle progression by its interaction with p53, p27 and cyclindependent kinases. In the TP53-mutant nasopharyngeal cell lines HONE1 and CNE1, UCHL1 formed
a complex with p53, MDM2 and p14ARF. Furthermore, it stabilized p53 protein by reducing the
ubiquitination of p53 and p14ARF while increasing the ubiquitination of MDM2, the E3 ubiquitin
ligase that typically targets p53 for degradation [124]. Overexpression of UCHL1 also induced p53
protein accumulation and loss of MDM2 in TP53-mutant MDA-MB-231 [143], LNCaP [127], and
HCT116 cells [144], as well as the TP53-wild type EC109 cells [144, 145].
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In a yeast two-hybrid screen, JAB1 was identified as an interacting partner of UCHL1 [112].
UCHL1 was found to colocalize and interact with JAB1, enhancing its role in promoting nuclear
export and degradation of p27. p27 is a tumor suppressor that inhibits cell cycle progression by
preventing the activation of cyclin E-CDK2, cyclin D-CDK4 and cyclin D-CDK6 [146]. UCHL1 has
also been shown to interact with and promote the kinase activity of CDK1, 4, and 5 in a cell-free
assay independent of its deubiquitinating activity; this effect was also seen for CDK4 and CDK5 in
vitro, as UCHL1 overexpression increased phosphorylation of their downstream targets, Rb and p27
[147].

Other putative UCHL1 targets
UCHL1 may enhance tumor cell survival by regulating the mTOR/AKT pathway. UCHL1
promoted AKT signaling by downregulating its negative regulator PHLPP1 [132]. In addition,
PHLPP1 translation is enhanced by mTOR complex 1 activity; UCHL1 destabilized mTOR complex
1, suggesting another mechanism through which AKT signaling is promoted [148].
UCHL1 may also promote angiogenesis: Goto et al. demonstrated a direct interaction
between UCHL1 and HIF-1α, preventing VHL-mediated ubiquitination of HIF-1α and promoting
HIF-1α protein stability [139].
The effect of UCHL1 on metastasis may be mediated through stabilization of the oncogenic
transcription factor, β-catenin, and promotion of β-catenin/TCF signaling [149, 150]. Interestingly,
UCHL1 transcription was in turn upregulated by β-catenin/TCF signaling to form a positive feedback
loop [149].
In addition to its deubuiquitinating enzyme activity, an ATP-independent E3 ligase ability has
been observed in vitro, which is dependent on UCHL1 dimerization [151]. Indeed, Karim et al. found
that UCHL1 increased K63-linked ubiquitination of TRAF6 [152].

14

CELL CYCLE PROGRESSION
In eukaryotic cells, the cell cycle is a unidirectional chain of processes that allows cells to
grow and duplicate. The cycle is split into two major stages: mitosis, where a cell divides into two
daughter cells, and interphase, which allows cells to grow and prepare for the next cycle of cell
division [153-155] (Figure 2).

Figure 2. Overview of the cell cycle.
Progression through the cell cycle is mediated by the cyclin-dependent kinases (CDKs), which are
activated when bound to their cyclin partners. While CDK protein levels are constant, transcription
and protein stability of the cyclin proteins fluctuate through the cycle. The G1 and G2-M checkpoints
ensure that cells with DNA damage do not divide, while the spindle-assembly checkpoint delays the
onset of anaphase until the chromatid pairs are correctly aligned. Intensity of black lines indicate the
protein levels of the cyclin proteins and the relative activity level of cyclin-CDK pairs.
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Interphase is composed of a DNA synthesis stage (S) sandwiched between two gap phases
(G1 and G2). Following the end of mitosis, cells enter G1 and undergo a period of growth and
increase in cellular content to prepare for the next round of DNA synthesis. In S phase, cells
synthesize a copy of the entire DNA contents in the nucleus, resulting in identical sister chromatids
that are bound together by the centromere [156]. The centrosome, i.e. microtubule organizing center,
is also replicated. Finally, G2 phase allows cells to prepare for mitosis. Cells may also exit the cell
cycle and enter a resting state known as G0 phase, where they do not prepare for DNA replication or
cell division.
Following G2, cells enter mitosis, which includes prophase, prometaphase, metaphase,
anaphase and telophase (Figure 3). During prophase, the chromosomes condense [157, 158]. In
addition, the two centrosomes migrate to opposite ends of the cell. At the end of prophase, nuclear
envelope breakdown is initiated in higher eukaryotes and continues into prometaphase. This begins
with the disassembly of nuclear pore complexes [159, 160], which is followed by depolymerization of
the nuclear lamina [161] and the absorption of the nuclear envelope proteins into the endoplasmic
reticulum [162, 163]. Loss of the nuclear envelope allows the microtubules to extend from the
cytoplasmic centrosomes into the nuclear space and attach to the kinetochores located on the
chromosomal centromeres.
By metaphase, the chromosomes reach their most compact configuration and complete their
alignment along the equatorial plane, i.e. metaphase plate, of the cell. In anaphase, the sister
chromatids separate, and the daughter chromosomes are pulled towards the centrosomes at opposite
ends of the cell [164, 165]. Finally, during telophase, a new nuclear envelope forms around each set
of daughter chromosomes, which begin to de-condense. Telophase is followed by cytokinesis, which
divides the cytoplasm and completes the division of a cell into two daughter cells [166].
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Figure 3. Overview of mitosis and cyclin B1-CDK1 localization.
For simplicity, only three chromatid pairs are shown.

Cyclin-dependent kinases (CDK) and cyclins
The progression of cells through the cell cycle is regulated by cyclin/CDK protein complexes
[155]. CDKs are serine/threonine protein kinases that are constitutively expressed, but only activated
at specific points in the cell cycle. Their regulation involves phosphorylation at several sites;
activation also requires binding to their specific cyclin protein partners. Unlike CDKs, cyclin protein
expression fluctuates throughout the cell cycle.
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When cells exit the G0 resting phase and enter G1, CDK4 and CDK6 complex with cyclin D1 to
phosphorylate the transcriptional repressor retinoblastoma protein (pRb), thus releasing the E2F
transcription factor from repression [155, 167]. In late G1, cyclin E-CDK2 continues phosphorylation
of Rb, promoting G1-S transition. Cyclin A2-CDK2 is required for DNA replication in the S phase,
while cyclin A2-CDK1 promotes G2-M transition. Lastly, cyclin B1 and CDK1 complex together to
form the mitosis-promoting factor and induce mitosis [153, 154].

Cyclin B homologs
Five cyclin B homologs have been identified in higher eukaryotes, three of which (B1, B2,
B3) are found in human tissue [168]. Of these, cyclin B1 (CCNB1) and cyclin B2 (CCNB2) exhibit
protein accumulation prior to mitosis and interact with CDK1 [169, 170]. Cyclin B1-CDK1 is
predominantly cytoplasmic during interphase and translocates to the nucleus at the onset of mitosis.
On the other hand, cyclin B2-CDK1 colocalizes to the golgi apparatus during both interphase and
mitosis. Thus, Cyclin B1-CDK1 is the primary regulator of mitosis, promoting chromosome
condensation, microtubule reorganization and solubilization of the nuclear lamina, while Cyclin B2CDK1 is restricted to promoting disassembly of the golgi apparatus during mitosis [171]. Indeed,
mice that are CCNB1-null die in utero, while CCNB2-null mice develop normally and are fertile,
despite a smaller body weight compared to wild-type mice [172]. Cyclin B3 (CCNB3) is a nuclear
protein that is restricted to the testis in adult tissue; it does not interact with CDK1, but binds to
CDK2 and is able to activate it, albeit poorly [173].

Regulation of cyclin B1 expression
Cyclin B1 undergoes strict temporal regulation (Figure 3). Cyclin B1 mRNA transcription
and stability increases from late S phase onwards, leading to accumulation of cyclin B1 protein [174].
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During metaphase, cyclin B1 is targeted for proteasomal degradation due to ubiquitination by the
anaphase-promoting complex (APC), a multi-unit E3 ligase. Cyclin B1 is therefore rapidly degraded
during the metaphase-anaphase transition, immediately after inactivation of the spindle-assembly
checkpoint, returning to a low level of protein expression that persists through G1 [175-177].
Following mitosis, the APC continues ubiquitination of cyclin B1 throughout G1; APC activity
ceases in S phase due to phosphorylation by cyclin A1-CDK2 and interaction with the inhibitory
regulator Emi1 [178, 179]. K48-linked ubiquitination is the canonical signal for degradation, but in
vitro studies have shown that cyclin B1 can also be targeted for degradation by K11- and K63-linked
ubiquitination, as well as multi-monoubiquitination [180-182].

CDK1 regulation
CDK1 activity is regulated by cyclin A and cyclin B binding, and by the balance of inhibitory
and activating phosphorylation at specific amino acid residues. CDKs and cyclins bind to each other
via the cyclin box, a motif found in cyclin proteins that also serves to activate their CDK binding
partner [183, 184]. Starting at late S and early G2, cyclin B1 begins binding to CDK1 as it is
increasingly expressed, causing accumulation of cyclin B1-CDK1 complexes. These complexes are
kept mostly inactive until the end of G2 through phosphorylation at a threonine and tyrosine residue
(Thr14/Tyr15), both of which are within the ATP-binding site [183]. Phosphorylation of these
residues therefore prevent binding with ATP. WEE1 resides in the nucleus and phosphorylates CDK1
at Tyr15 [185, 186], while MYT1 resides in the golgi apparatus and endoplasmic reticulum, and
phosphorylates both residues [187, 188]. In turn, CDK1 is activated when CDC25 phosphatase
gradually removes the phosphorylation at these sites [189].
Activation of CDK1 also requires phosphorylation at threonine 161 (Thr161) by the CDKactivating kinase (CAK). This only occurs after CDK1 complexes with cyclin B1, as Thr161 is
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inaccessible to CAK when CDK1 is monomeric; binding of CDK1 to cyclin B leads to
conformational changes that exposes Thr161 to CAK [190-192].
With gradual Thr14/Tyr15 dephosphorylation and Thr161 phosphorylation through the G2
phase, cyclin B1-CDK1 complexes reach a low level of activation by the end of G2. In Xenopus egg
extracts, approximately 30% of maximum activity is reached by the end of G2 [170, 193, 194].
Accumulation of cyclin B1-complex levels reach a threshold by this point, initiating a positivefeedback loop that inhibits WEE1 and activates CDC25, leading to rapid and complete activation of
CDK1 [195].

Spatial regulation of the cyclin B1-CDK1 complex
During interphase, the inactive cyclin B1-CDK1 complex is continuously shuttled between
the nucleus and cytoplasm; however, it is predominantly cytoplasmic, due to a higher rate of nuclear
export versus import. This is mediated by the cytoplasmic retention signal (CRS) within the cyclin B1
protein, which in turn contains the nuclear export signal (NES). The NES binds to the nuclear
transport receptor CRM1, which mediates export of the cyclin B1-CDK1 complex from the nucleus
[196, 197]. During early prophase the affinity of CRM1 for cyclin B1 is greatly reduced when the
CRS is phosphorylated, reducing the export rate and leading to accumulation in the nucleus prior to
breakdown of the nuclear envelope [176, 198, 199].
There is partial retention of activated cyclin B1-CDK1 in the cytoplasm, which is needed to
activate mitotic processes such as microtubule rearrangement and nuclear envelope breakdown [200].
In addition, a fraction of cyclin B1-CDK1 complexes translocates to the mitochondrial matrix to
upregulate mitochondrial respiration and oxygen consumption. The resulting increase in ATP
provides the energy needed for successful G2-M transition [201]. It has been suggested that this
continuous shuttling between the nucleus and cytoplasm allows the complex to receive integrated
input from both compartments before determining if mitosis should proceed; for example, this can
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ensure that the DNA damage checkpoint is passed in the nucleus before the complex is activated and
initiates mitotic processes in the cytoplasm [196].
After nuclear envelope breakdown, cyclin B1-CDK1 continues its association with the
centrosomes [202], microtubules [169] and chromosomes [177, 203] in prometaphase before the
spindle-assembly checkpoint is activated at the metaphase-anaphase transition and cyclin B1 is
degraded.

Targets of CDK1
CDK1 substrates are phosphorylated at a minimal or complete consensus motif, S/T-P or S/TP-X-R/K [204, 205]. Over 300 CDK1 substrates have been identified in budding yeast [206].
However, information on CDK1 substrates in vertebrates is currently less established. Recent
attempts have been made to identify CDK1 substrates in vertebrates; for example, Petrone et al.
performed phosphoproteomics analysis of HeLa cells, using the CDK1 inhibitors Flavopiridol and
RO-3306. Inhibition of CDK1 reduced the phosphorylation of 1215 phosphopeptides on 551 proteins
[207]. Using chicken DT40 cells, Ohta et al. isolated and analyzed proteins associated with
chromosomes during mitosis, identifying 4274 phosphorylation sites in 1014 proteins, of which 350
sites underwent mitosis-specific phosphorylation [208]. Nevertheless, it is known that CDK1
regulates proteins that mediate mitotic processes; the main known substrates in vertebrates will be
discussed.
CDK1 initiates chromosome condensation and assembly by phosphorylation of Histone H1
[209, 210], Kif4A [208], topoisomerase Iiα [208] and the condensin I [211] and II complexes [212].
To induce nuclear envelope breakdown, CDK1 phosphorylates nucleoporins [213-216], leading to
disassembly of nuclear pore complexes and complete nuclear envelope breakdown. In addition,
phosphorylation of lamin proteins causes disassembly of the nuclear lamin [217, 218].
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Mitosis requires dramatic rearrangement of the microtubule network, leading to formation of
the mitotic spindle. CDK1 regulates microtubule dynamics by phosphorylation of tubulin, which
polymerizes to form microtubules [219], and microtubule- and tubulin- binding proteins [220, 221].
For correct kinetochore-microtubule attachment [203], CDK1 phosphorylates kinetochore-associated
proteins during prometaphase, required for correct attachment of the microtubules to kinetochores.
One such substrate at the unattached kinetochore is Cdc20; phosphorylated protein is bound to Mad2,
maintaining the APC in an inactive state. After successful attachment, cyclin B1-CDK1 is displaced,
Mad2 is no longer bound and is subsequently able to activate the APC [203].
CDK1 also promotes inactivation of itself at the end of mitosis by phosphorylating APCrelated proteins, as will be discussed later.

Cyclin B1 in cancer
While normal cells are cyclin B1-negative outside of mitosis, unscheduled cyclin B1
expression in interphase has been observed in cancer cells lines and tumor samples [222-225];
overexpression of cyclin B1 has also been associated with increased mitosis, grade and poorer
disease-free survival and/or overall survival [226-228]. In endometrioid endometrial cancer, cyclin
B1 levels – as measured by immunohistochemistry – were associated with increasing grade, stage and
poorer cancer-specific survival by univariate analysis [229].
The overexpression and/or unscheduled expression of cyclin B1 may be due to aberrant
cyclin B1 expression or impaired degradation. Uncontrolled cyclin B1 expression can disrupt control
of cell cycle progression. For example, the injection of cyclin B1 mRNA into Xenopus embryos
shortens the cell cycle length [194, 230]. In addition, overexpression of cyclin B1 can allow cells to
overcome G2-M arrest [231, 232].
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Cell cycle checkpoints
Several checkpoints exist in the cell cycle (Figure 2). The G1 checkpoint ensures that there is
an absence of DNA damage before proceeding to S phase; the major signaling pathway is the
ATM/ATR-CHK2/CHK1-p53/MDM2/p21 pathway [233]. Detection of DNA damage by the ATM
and ATR kinases leads to phosphorylation of p53 and its stabilization and accumulation. p53 then
induces the transcriptional activity of p21, which inhibits cyclin E-CDK2 to induces G1 arrest [234,
235].
The G2-M checkpoint also ensures that there is no DNA damage or errors in chromosome
replication before cells enter mitosis. p38 and/or ATM/ATR are activated [236], which ultimately
results in inactivation of cyclin B1-CDK1 activity through several possible mechanisms [235, 237,
238] and G2 arrest. While p53 is critical for mediating the G1 checkpoint, its role in G2-M
checkpoint activation is redundant [239, 240]. However, p53 has been shown to suppress cyclin B1
transcription during induction of the G2-M checkpoint, as the cyclin B1 promoter contains a p53sensitive region [231, 241].
The spindle-assembly checkpoint ensures that the duplicated sister chromatids are equally
divided and correctly attached to the microtubules before anaphase begins [242]. As discussed later,
the checkpoint proteins maintain APCCdc20 in an inactive state until the checkpoint is overcome.
Defects in the spindle-assembly checkpoint contribute to chromosomal instability and subsequent
aneuploidy.

The anaphase-promoting complex
The two major E3 ubiquitin ligases involved in the cell cycle are the Skp1/Cullin/F-box
(SCF) and the anaphase-promoting complex (APC) [243, 244]. While the SCF acts mostly during the
G1-S and G2-M transitions, the APC is essential for metaphase-anaphase transition. The APC is
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nuclear during interphase; during mitosis, it associates with proteins involved in the spindle-assembly
checkpoint located at kinetochores [245].
The APC complex is composed of at least 11 subunits in vertebrates [244]. Of these, the
cullin subunit APC2 and RING-H2 domain subunit APC11 make up the catalytic core, while Cdc20
and Cdh1 are the co-activator subunits that interact with APC at different times in the cycle to
mediate the recognition and binding of different substrates [243]. There are several amino acid motifs
recognized by the Cdc20 and/or Cdh1. For example, the “destruction box” (D box), first identified in
cyclin B proteins [246], is recognized by both Cdc20 and Cdh1, while the KEN box is only
recognized by Cdh1 [247]. The KEN box is also present in Cdc20, as Cdc20 itself is an APCCdh1
substrate.
The APC is regulated by phosphorylation and interaction with several inhibitor proteins,
which ensure that the APC is kept inactive until the spindle-assembly checkpoint is overcome [248].
Therefore, cyclin A and B are allowed to accumulate until the onset of mitosis, and the separation of
sister chromatids during APC-induced anaphase does not occur until the chromosomes are correctly
aligned at the metaphase plate and attached to the microtubules.
The inhibition of free APC by Emi1 begins in S phase, which prevents APC-Cdc20 binding
[249]. Emi1 is degraded during prophase, but inhibition is continued by RASSFA1 until late
prometaphase [250]. At this point, the APC is phosphorylated by CDK1 and polo-like kinase 1 [251253], allowing Cdc20 to bind and initiate degradation of cyclin A and Nek2A at the prometaphasemetaphase transition. These substrates have a modified D box that allows them to be degraded while
the APCCdc20 is otherwise kept inactive by Mad2-Bub3-BubR1, a complex of spindle-assembly
checkpoint proteins associated with unattached kinetochores [243, 254, 255]. Once the chromatids are
correctly aligned and checkpoint is overcome, the Mad2-Bub3-BubR1 complex dissociates from
APCCdc20 to allow its full activity, initiating degradation of cyclin B at the metaphase-anaphase
transition [255]. APCCdc20 is then ubiquitinated and inactivated by APCCdh1, which continues
degradation of cyclin B1 from late anaphase through to G1. Finally, Cdh1 is phosphorylated by
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CDK1 at the G1-S transition [251], causing it to dissociate from APC, which is once again inhibited
by Emi1. Cdh1 remains phosphorylated until the next round of mitosis, when APCCdc20 begins cyclin
B degradation and CDK1 activity begins to decrease [243].

SUMMARY OF PROBLEMS AND HYPOTHESIS

There are currently 7000 or fewer new cases of UPSC per year in the US; as a result, few
therapeutic targets are being studied. In addition, conducting studies that focus solely on this rare
subtype have been a constant challenge, making it difficult to determine optimal treatment strategies
[78]. Most large trials combine all endometrial subtypes, with UPSC making up only a small
percentage of cases. The purpose of this study was to identify novel therapeutic targets that could aid
in the management of UPSC. As of May 2013, the TCGA dataset for endometrial cancer contained 91
UPSC cases with both clinical and RNA sequencing data. This relatively large sample size allows a
meaningful comparison to be made between UPSC and EEC to identify relevant genetic differences.
To determine genetic changes that are responsible for the increased aggressiveness and
poorer survival outcomes in UPSC compared to favorable type I tumors, we analyzed the RNA
sequencing data from The Cancer Genome Atlas (TCGA) to identify genes differentially expressed
between grade 1/2 endometrioid carcinomas and UPSCs. In particular, we identified UCHL1 as a
gene that was more strongly expressed in UPSCs than in endometrioid carcinoma and normal
endometrium, and whose expression level was associated with poorer overall survival. These findings
were validated through immunohistochemical analysis of an independent cohort of tumor samples.
Based on these findings, and the fact that UCHL1 is a deubiquitinating enzyme known to
affect the protein stability of various cancer-related proteins, the hypothesis tested in this dissertation
is that UCHL1 contributes to UPSC tumor progression by modulating the protein stability of target
genes.

25

Our specific aims are as follows:
1. To identify important genes of interest in UPSC.
a. Identify differentially expressed genes between normal endometrial tissue and the
different subtypes of endometrial cancer.
b. Confirm upregulation of UCHL1 in an independent sample cohort.
2. To delineate the functional role of UCHL1 in UPSC tumor progression.
3. To determine the mechanisms through which UCHL1 modulates UPSC tumor progression.

26

CHAPTER 2:
MATERIALS AND METHODS
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TCGA analysis
TCGA data sets
Data was directly downloaded from the TCGA Data Portal. Clinical data was downloaded on May
2013. Patients with stage IIA were converted to I in accordance with the 2009 revisions to the
surgical staging system for endometrial carcinoma by the International Federation of Gynecology and
Obstetrics (FIGO) [256, 257]. Overall survival duration was inferred from “days to death” since
initial diagnosis for deceased patients, whereas overall survival duration for censored patients was
derived from “days to last known alive” and “days to last follow-up”. Survival data was updated with
the additional v1.7 and v2.0 follow-up information as released by the TCGA Data Portal. Level 3
RNAseqV2 data was downloaded on May 2013 and included the global expression profiles of 21
normal, 87 EEC grade 1, 100 EEC grade 2, 161 EEC grade 3, 15 mixed EEC/UPSC and 91 UPSC
samples. Normalized RSEM data was used for principal component analysis (PCA), while raw counts
were used for Significance Analysis of Microarrays (SAM). Level 3 RPPA data was downloaded on
May 2014 and included 171 EEC samples, 3 mixed UPSC/EEC samples, and 22 pure UPSC samples
for which concurrent clinical and RNAseqV2 data were available.

Principal component analysis
Level 3 normalized RSEM data for normal, EEC, mixed and pure UPSC samples was used for PCA
analysis. The signal-to-noise (SNR) ratio of each gene was calculated by dividing the mean
expression value across patients over its standard deviation. The data was then filtered to remove
genes with a log10 SNR 2 standard deviations below the mean. The 500 genes with the highest
variance were selected for analysis; values were log2 transformed and mean-centered before analysis
using the “prcomp” function in R.
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Significance Analysis of Microarrays (SAM)
The SAM method for sequencing data (version 4.0; Stanford University Labs) was used to identify
differentially expressed (DE) genes between low-grade EEC and pure UPSC. Raw counts from the
level 3 data for RNAseqV2 were filtered to remove genes with 10 or less reads across all samples, or
genes with an average of 0.5 or less across all samples. The remaining 19093 genes were then
converted to integers for analysis. For each comparison, two-class (unpaired) analysis was used, and
the number of permutations was set to 100. q-values were obtained for each gene. Genes were
considered DE if q < 0.05 and the SAM calculated fold change ≥ 2.

Automated log-rank test of genes in the RNA sequencing data set
A two-sample log-rank test for overall survival was calculated for every significant gene identified
from the SAM assessment using level 3 normalized RSEM data for all 91 pure UPSC samples (57
initial samples plus an additional 34). Vital status and overall survival time were extracted from
clinical data as previously described. For each gene, patients were assigned to one of two groups:
below or above the median expression value. A loop in R statistical software (version 2.15.0, R
Foundation for Statistical Computing) was used to perform the “survdiff” function from the package
“survival” on each gene. The computed p-values were extracted for each gene. Hazard ratio was
calculated for each gene (above median/ below median) by HR = (O1/E1)/(O2/E2), where O1 and O2
are the observed number of deaths in the groups below and above the median respectively, and E1 and
E2 are the expected number of deaths in the groups below and above the median respectively.

Pearson’s test of correlation between UCHL1 RNA expression and RPPA data
Of the pure UPSC samples within the RNA sequencing dataset, 22 also had RPPA data available (3
of which were mixed EEC/UPSC). Using these 22 samples, we performed Spearman’s test of
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correlation to determine the correlation between UCHL1 RNA expression and each of the 166 protein
probes. For probes with p<0.05, Spearman’s test was also performed with their RNA expression
levels against UCHL1 RNA expression levels.

Materials
Clinical specimens
All samples and clinical data were collected following approval by the MD Anderson Institutional
Review Board. Formalin-fixed, paraffin-embedded sections of UPSC, EEC and normal tissue samples
were obtained from The University of Texas MD Anderson Gynecologic Cancer Translational
Research Tissue Bank. Normal premenopausal uterine samples were from individuals without cancer,
while normal postmenopausal uterine samples were from tissue adjacent to tumor. Prior to the
collection of these samples, informed consent had been obtained from patients undergoing primary
cytoreductive surgery from 1989 through 2012. Overall survival time was measured from the date of
diagnosis onwards.

Cell culture and reagents
Human endometrial carcinoma cell lines ECC1, HEC-1A, HEC-1B, HEC-50, HEC-59, Ishikawa,
MFE-296, MFE-280 and RL-952 (ATCC) were cultured in RPMI-1640 supplemented with 2 nM Lglutamine (Invitrogen) and 10% fetal bovine serum. Human UPSC cell lines ARK1 and ARK2 were a
kind gift from Dr. Alessandro D. Santin (Yale Cancer Center), and UPSC cell lines ACI-126 and
ACI-158 were a kind gift from Dr. John I. Risinger (Michigan State University). All four cell lines
were cultured in DMEM supplemented with 1.0 g/L glucose, L-glutamine, sodium pyruvate (Corning
Cellgro) and 10% fetal bovine serum. All cell lines were grown at 37 ̊C in a humidified incubator
with 5% CO2. UCHL1 was transiently silenced by transfection with Silencer® select siRNAs (s14616
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and s14618, Life Technologies) duplexed with Lipofectamine RNAiMAX (Life Technologies) at a
final concentration of 5 nM. Non-targeting Silencer® select siRNA was used as a negative control
(4390843, Life Technologies). Transient expression of UCHL1 was achieved by transfection with the
cDNA encoding human UCHL1 in a pReceiver-02 vector (EX-T2880-M02, GeneCopoeia).

Stable transfectants
ARK1 cells transduced with lentiviral particles containing CMV-firefly luciferase (PLV-10064,
Cellomics Technology) were selected for with G418. Successful transduction was confirmed by in
vitro luciferase detection assay. To generate ARK1 cells with doxycycline-inducible control shRNA
(ARK1-luc-dox-shNT) or UCHL1 knockdown (ARK1-luc-dox-shUCHL1), luciferase-labelled cells
were transduced with TRIPZ inducible lentiviral non-silencing control (RHS4743, Dharmacon) or
TRIPZ inducible lentiviral shRNA against UCHL1 (RHS4696-200764988, Dharmacon), and selected
for with puromycin. Induction of UCHL1 knockdown by 2µg/ml doxycycline treatment of ARK1luc-dox-shUCHL1 was confirmed in vitro by western blot.

Antibodies
Anti-cyclin B1 from Santa Cruz (sc-245) was used for immunohistochemistry, western blot,
immunoprecipitation, immunofluorescence and the proximity ligation assay. Anti-UCHL1 from
Sigma-Aldrich (HPA005993) was used for immunohistochemistry, immunofluorescence and
proximity ligation assay; anti-UCHL1 from Cell Signaling (11896) was used for western blot; antiUCHL1 from R&D Systems (MAB6007) was used for immunoprecipitation. Additional antibodies
used for western blot include anti-cyclin D1 (sc-753, Santa Cruz), anti-cyclin E (sc-481, Santa Cruz),
anti-p53 (48818, Cell Signaling), anti-ubiquitin (3936, Cell Signaling), anti-β-actin (4967, Cell
Signaling), anti-β-catenin (9562, Cell Signaling), anti-GSK3α/β (5676, Cell Signaling), anti-p21 (sc-
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397, Santa Cruz), and anti-p27 (sc-529, Santa Cruz). MMP-13 (sc-30073, Santa Cruz) was used for
immunofluorescence and the proximity ligation assay.

Experimental procedures
Immunohistochemical analysis
Immunohistochemical staining was performed on paraffin embedded tissue. Slides were
deparaffinized and rehydrated before antigen retrieval in citrate buffer (S2307, Poly Scientific), in a
decloaking chamber (Biocare Medical) at 125 ̊C for 4 minutes and 90 ̊C for 1 minute. Slides were
then stained with primary and secondary antibody using the Lab Vision Autostainer 360 (Thermo
Fisher Scientific). Using a light microscope, digital photomicrographs of representative areas were
taken for each slide at x20 magnification; the staining intensity for each slide was then quantified at
least 3 times using the Image-Pro Plus software (version 17, MediaCybernetics) by drawing around
the stained tumor tissue and obtaining an intensity score from 0 (pure black) to 255 (pure white) with
background correction. An average value was calculated for each slide and transformed linearly onto
a scale of 0 to 1 for further survival analysis. Slides were also stained with anti-cyclin B1 antibody,
and the percentage of tumor cells positive for cyclin B1 was determined by visual observation under a
light microscope.

TP53 DNA sequencing
Using DNA extracted from ARK1 and ARK2 cells, exon 5-8 of the TP53 gene were amplified by
PCR. The primers used were as follows: exon 5-6, forward 5’-TGTTCACTTGTGCCCTGACT-3’,
reverse 5’-GAGGGCCACTGACAACCA-3‘; exon 7, forward 5’AGGTCTCCCCAAGGCGCACTG-3’, reverse 5’-TGTGCAGGGTGGCAAGTGGC-3’; exon 8,
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forward 5’-TGGGAGTAGATGGAGCCTGG-3’, reverse 5’-AGGAAAGAGGCAAGGAAAGG-3’.
Amplified DNA fragments were analyzed by Sanger sequencing.

Quantitative RT-PCR
Total RNA was extracted from adherent cells using the PureLink RNA mini kit (Life Technologies)
per the manufacturer’s instructions. Total RNA (1 μg per sample) was subjected to reverse
transcription for the synthesis of single-stranded cDNA using the high-capacity cDNA reverse
transcription kit (Applied Biosystems). Real-time PCR detection was performed using the TaqMan
universal master mix (no uracil-N-glycosylase; Applied Biosystems), PPIA-, UCHL1- and cyclin B1specific TaqMan gene expression assays (Hs04194521_s1, Hs00985157_m1 and Hs01030099_m1,
Applied Biosystems) and the CFX96 Touch real-time PCR detection system (Bio-Rad Laboratories).
PPIA expression levels were used as a reference to quantify UCHL1 and CCNB1 RNA expression
levels via the relative standard curve method.

Western blot analysis
Adherent cell cultures were washed twice with PBS and lysed with RIPA buffer (150 mM NaCl,
1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) (SigmaAldrich) supplemented with protease inhibitor cocktail (Sigma-Aldrich). Protein concentration was
determined by the BCA assay (Pierce). Protein lysates were separated on SDS-polyacrylamide gel
and electrophoretically transferred to PVDF membrane (Bio-Rad Laboratories). Membranes were
incubated with primary antibodies overnight at 4 ̊C, then incubated with the HRP-conjugated
secondary antibodies (GE Healthcare Life Sciences) for 1 hour at room temperature. Signals were
developed using the HyGlo quick spray chemiluminescent kit (Denville Scientific) and visualized on
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autoradiography film (Denville Scientific). Relative protein levels were quantified with ImageJ
(version 1.50i, National Institutes of Health) by normalizing to β-actin.

Apoptosis assay
Apoptosis was measured in ARK1 cells by using the Dead Cell Apoptosis Kit (V13241, Invitrogen)
per the manufacturer’s instructions. Cells were stained with Alexa Fluor 488 annexin V and
propidium iodide, then read a Gallios flow cytometer (Beckman Coulter). Cells with both propidium
idodide and annexin V were considered apoptotic.

Migration assay
Three days after siRNA transfection, ARK1 and ARK2 cells were serum starved for 24 hours; equal
numbers were then plated into migration chambers with 8 µm pore size, (3422, Corning) in serumfree medium. Medium supplemented with 20% fetal-bovine serum was placed below the chamber.
Cells were allowed to migrate for 24 hours before fixation with ice-cold methanol and staining with
crystal violet solution.

Cell sensitivity to chemotherapeutic agents
Cisplatin (Pfizer) and paclitaxel (Hospira) were obtained from the M.D. Anderson Cancer Center
pharmacy in solution. Following siRNA-mediated knockdown of UCHL1, ARK1 and ARK2 cells
were treated with a range of doses of paclitaxel or cisplatin for three days before analysis by MTT
assay. Dose-response curves were generated for each drug.
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MTT assay
Cell proliferation was measured by the MTT assay. Cell cultures were incubated for 2 hours at 37 ̊C
in 0.5 mg/ml thiazolyl blue tetrazolium bromide (MTT) in medium, after which the mixture was
aspirated and replaced with DMSO. Absorbance was measured at 590 nm using a FLUOstar Omega
plate reader (BMG Labtech). Experiments were performed in triplicate.

In vivo UCHL1 knockdown study
Six-week old, female nude mice received an injection of luciferase-expressing, doxycycline-inducible
ARK1-luc-dox-shNT cells or ARK1-luc-dox-shUCHL1 cells. 6 x 106 Cells were injected
intraperitoneally in a 200 µl mixture of 2:1 PBS:matrigel. One day after injection, mice were
switched from the standard diet to an irradiated diet containing 625 mg/kg doxycycline (TD.01306,
Harlan) to induce shRNA expression. To compare survival outcomes between the two groups, mice
were sacrificed when moribund and tumors were collected for immunohistochemical analysis.

Establishment of ARK1 subclones from ascitic fluid
Ascites from five mice in the control group were collected to isolate ARK1-luc-dox-NT cells with
improved ability to establish tumor in vivo. For each sample, 1 ml of ascites was plated onto a culture
plate with DMEM and 10% fetal bovine serum. Medium was replaced the next day to remove nonadherent cells. After 2 passages, adherent cells were confirmed to be ARK1-luc-dox-NT cells by
doxycycline treatment and confirmation of induced RFP activity. Separately, Asc-ARK1-luc-dox-NT
cells were cultured in medium without doxycycline and passaged twice before long-term freezing.
One of the subclones were used for the following in vivo experiment.
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In vivo LDN-57444 treatment
For the LDN-57444 treatment study, six-week old, female nude mice were injected with 6 x 106 AscARK1-lux-dox-NT cells cultured without doxycycline. Cells were injected intraperitoneally in a 200
µl mixture of 2:1 PBS:matrigel. After allowing tumors to establish for 2 weeks, the mice were
assigned randomly to the two groups and treated thrice weekly with 0.5 mg/kg LDN-57444 (Tocris
Bioscience, Bristol, UK) or control PBS with solvent (0.5% DMSO and 2.5% ethanol). LDN-57444
treatment continued until the mice became moribund, at which point they were sacrificed.

In vivo bioluminescence imaging
Imaging of tumors was performed using the IVIS Lumina XR imaging system (Caliper Life Sciences)
and signal quantification was done using Living Image Software (Caliper Life Sciences). Mice were
injected intraperitoneally with 120 mg/kg of luciferin, followed by induction of anesthesia with 2-3%
isoflurane gas. Bioluminescent images were acquired 10 minutes after injection.

Cycloheximide chase assay
ARK1 and ARK2 cells were treated with 20 µg/ml and 10 µg/ml CHX respectively before cell lysis
at the indicated time points for analysis by western blot. Cyclin B1 protein expression levels were
determined relative to zero hours of cycloheximide treatment.

Immunoprecipitation and co-immunoprecipitation
For co-immunoprecipitation studies, cells were harvested in Pierce IP lysis buffer (Thermo Fisher
Scientific). 1-2mg of protein lysate were precleared with 20ul Protein A/G beads for 60 minutes at 4˚
C, then incubated with 4 ug antibody overnight at 4˚ C. 40 ul Protein A/G were added the next day to
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pull down bound protein-antibody complexes, and proteins were eluted from the beads with
denaturing SDS buffer. For western blot analyses, TrueBlot HRP-conjugated anti-rabbit and antimouse antibodies (18-8816-33 and 18-8817-33, Rockland) were used to minimize detection of lightand heavy-chain antibody fragments. For detection of cyclin B1 ubiquitination, cells were pretreated
with 25 μg/ml MG132 for 4 hours before harvesting in RIPA buffer with protease inhibitor and PR619 (25 μM). Ubiquitin staining was quantified with ImageJ (version 1.50i, National Institutes of
Health) and normalized to cyclin B1 staining following immunoprecipitation (IP: cyclin B1 – WB:
cyclin B1).

Immunofluorescence and Duolink proximity ligation assay
Cells were plated on coated glass slides overnight before fixation with methanol. Slides were blocked
with 1% bovine serum albumin (BSA), then incubated with primary antibodies in 1% BSA. For
immunofluorescence staining of UCHL1 and cyclin B1, secondary antibodies used were Alexa Fluor
488 anti-rabbit (A-11032) and Alexa Fluor 596 anti-mouse (A-11034) from Thermo Fisher. For
detection of protein interaction between UCHL1 and cyclin B1, incubation with primary antibody
was followed by use of the Duolink In Situ kit (#DUO92101, Sigma-Aldrich) per the manufacturer’s
instructions. Cells were visualized on the Olympus FV1000 laser confocal microscope.

Double thymidine cell synchronization
ARK1 cells were synchronized in early S phase by 16 hours of thymidine treatment (2 mM) in normal
culture medium, followed by 10 hours release in culture medium, and a second thymidine block of 14
hours. Cells were then collected for analysis 10 hours after the second release to enrich for mitotic
cells.
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Cell cycle analysis by flow cytometry
Adherent cells were trypsinized, washed once with PBS, and fixed overnight at 4 C
̊ with 70% ethanol.
Cells were then incubated with 0.1 mg/ml RNase A solution and 50 μg/ml propidium iodide at 37 ̊C
for 30 minutes. Stained cells were subsequently analyzed using a Gallios flow cytometer (Beckman
Coulter) to determine the percentage of cells in the G1, S and G2/M phases.

Statistical analyses
Survival analysis was performed with SPSS software version 19 (IBM Corporation). Median follow
up times were calculated by the reverse Kaplan-Meier method [258]. The Kaplan-Meier log-rank test
was used for univariate analysis, while cox regression was used for multivariate analysis. Statistical
analysis was performed with SPSS and GraphPad PRISM version 6. Comparisons between groups
were performed using the Mann-Whitney U-test or the Kruskal-Wallis H-test for multiple groups.
Following Kruskal-Wallis analysis, post-hoc testing for nonparametric pairwise multiple comparisons
was performed with the Dunn’s test to determine differences between each pair of groups. The
adjusted p-values for multiple comparisons was calculated by p*n*(n-1)/2, where n is the number of
independent groups. Correlation between variables was tested using the Spearman’s test for
nonparametric data.
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CHAPTER 3:
UCHL1 IS UPREGULATED IN UPSC
AND IS ASSOCIATED WITH POORER SURVIVAL OUTCOMES
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Specific Aim 1. To identify important genes of interest in UPSC.
a. Identify differentially expressed genes between normal endometrial tissue and the
different subtypes of endometrial cancer.
b. Confirm upregulation of UCHL1 in an independent sample cohort.

Principal component analysis reveals distinct clusters based on RNA expression profiles

It is known that UPSC is clinically distinct from EEC and also genetically different, with a high
percentage of TP53 mutation and HER2/neu overexpression. However, the global genetic profile of
UPSC is less clear. To begin to understand the molecular pathogenesis of UPSC, we explored its
relationship to normal endometrial tissue and other endometrial carcinomas by principal component
analysis.
At the time of download, the TCGA endometrial dataset for RNAseq version 2 contained 21
normal, 87 EEC grade 1 (EEC1), 100 EEC grade 2 (EEC2), 161 EEC grade 3 (EEC3), 15 mixed
EEC/UPSC and 91 UPSC samples. Using the level 3 normalized RSEM data, 500 genes with the
highest variance were selected for analysis. Figure 4A displays the clustering of samples according to
the first two principal components, while Figure 4B includes the first three components. Though only
accounting for 26.1% and 32.9% of explained variance respectively, the first two and three
components were able to separate normal samples from tumor samples, and also illustrated the
clustering together of EEC grade 1 and 2. There was a large variation within the normal tissue
samples, with some overlap between the normal cluster and the EEC clusters. Interestingly, grade 3
EEC tumors overlapped with low grade EEC and also UPSC and mixed EEC/UPSC tumors. UPSC
samples were clustered away from both normal tissue and EEC1/2.
These findings suggest that pure and mixed UPSC are the most genetically different from
normal tissue, suggesting that they have the highest degree of dysregulation at the RNA level. UPSC
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is known to have a high number of somatic copy number alterations compared to EEC [259], which
could explain this high number of aberrations. It also suggests that there are certain similarities
between high grade EEC and UPSC.

Figure 4. Principal component analysis of RNA expression profiles across endometrial tissue
samples.
(A) Scatter plot of first two principal components. 95% confidences ellipses assume a multivariate tdistribution.
(B) 3D plot of the first three principal components.
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SAM analysis for the identification of differentially expressed genes between tumor subtypes

Next we sought to further explore differences between different histological subtypes of
endometrial carcinoma by identifying differentially expressed (DE) genes between normal and tumor
samples, and also between different tumor subtypes. SAM analysis for sequencing data [260] was
used to perform two-class, unpaired comparisons between the RNA sequencing profiles of tumors
(EEC1, EEC2, EEC3 and UPSC) and normal samples; comparisons between different tumor subtypes
were also performed. Level 3 raw read counts from the TCGA RNAseq Version 2 data set were used.
Comparisons between grade 1 and 2 EEC yielded no genes with significantly higher expression in
grade 2 versus grade 1 EEC, suggesting that these two groups were relatively similar in gene
expression; therefore, these two groups were merged together for tumor-tumor comparison analysis.
Genes with q < 0.05 and fold change ≥ 2 were considered differentially expressed. A total of
9506 genes were DE in one or more normal-tumor analyses; of these, 4575 genes (48%) were
significant in all comparisons. As expected, normal-EEC1 and normal-EEC2 comparisons showed the
greatest overlap of significant genes, while normal-UPSC comparison had the least overlap with other
normal-tumor comparisons (Figure 5A and B).
When comparing different tumor subtypes, EEC1/2-UPSC comparisons yielded a larger
number of DE genes than EEC3-UPSC, suggesting a larger genetic difference between EEC1/2 and
UPSC (Figure 5C). EEC1/2-EEC3 comparison yielded the least DE genes, again illustrating that the
global expression profile of UPSC is the most distinct from low and high grade EEC. A large number
of genes were DE in both the EEC1/2-UPSC and EEC3-UPSC comparisons, which may represent
genetic changes that are an indicator of increased aggressiveness as opposed to being specific to a
histological type.
In accordance with the principal component analysis results, the SAM analysis output
illustrates that EEC1 and EEC2 are genetically most similar, and EEC3 is more similar to UPSC than
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EEC1/2 is to UPSC. The intermediate clinical prognosis of EEC3 between low grade EEC and UPSC
is therefore reflected in dysregulation at the RNA level.
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Figure 5. Venn diagrams of differentially expressed genes in SAM analyses.
Genes with q < 0.05 and fold change ≥ 2 were designated as differentially expressed.
(A) Venn diagram showing the overlap of significant genes between different normal-tumor
comparisons.
(B) Percentage of genes overlapping between different normal-tumor comparisons.
(C) Venn diagram showing overlap between different tumor-tumor comparisons.

UCHL1 is upregulated in UPSC and is significantly correlated with shorter overall survival
time in the TCGA data set

As we observed an overlap between grade 3 EEC and UPSC based on expression profiles,
certain drivers of UPSC aggressiveness may also be dysregulated in EEC3; therefore, such genes may
not be identified through EEC3-UPSC comparison results. Instead, we chose to focus on the
comparison between UPSC and low-grade EEC (workflow in Figure 6).
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Figure 6. Discovery of genes that contribute to UPSC tumor progression.

To identify genes that contribute to the increased aggressiveness of UPSC, we extracted the
3340 genes differentially expressed between EEC G1/2-UPSC to see which were correlated with
overall survival in the TCGA data set. For each gene, samples were grouped above and below the
median expression level. A two-sample log-rank test of overall survival was then conducted, using
survival data from the 91 pure UPSC samples, to find the genes significantly correlated with overall
survival in the UPSC data set.
By overlapping survival information with the SAM analysis between EEC grade 1/2 and
UPSC, 145 genes were found to be differentially expressed between UPSC and low-grade EEC, and
which individually showed a significant association with overall patient survival as determined by the
log-rank test (p < 0.05) (Table 1 and Figure 7A). Of particular interest were the 19 genes that were
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significantly higher in UPSC compared to both normal tissue and low-grade EEC, and for which high
expression was associated with poorer overall survival (Table 2). Of these, we chose to study UCHL1
further, due to it being the most highly expressed in the UPSC group. UCHL1 exhibited over a 40fold increase in RNA expression from low-grade EEC to UPSC, with similar expression levels in
normal and low-grade EEC (Figure 7B). Both pure UPSC and mixed histology (UPSC/EEC) tumors
displayed significantly higher UCHL1 expression than normal endometrial tissue and EEC. An
intermediate level of UCHL1 expression was observed in grade 3 EEC, which was also significantly
higher than in low-grade EEC (Figure 7C). UCHL1 expression was not significantly different across
stages of UPSC, suggesting that its upregulation is an early event (Figure 7D). Furthermore, the copynumber high serous-like cluster, one of four novel groups recently identified using integrated
genomic data [259], also had a significantly higher UCHL1 expression than the other three clusters
(Figure 7E). Finally, high UCHL1 expression correlated with poorer overall survival duration by both
Kaplan-Meier analysis (Figure 7F) and multivariate Cox regression analysis (Table 3).
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Median RSEM value
Gene

Entrez ID
Normal

EEC
(G1/2)

SAM: UPSC vs normal

UPSC

q

d

Fold
change

SAM: UPSC vs EEC (G1/2)
q

d

Fold
change

Log-rank test
p

HR

TFF3

7033

288

8170

63

0.000

-461.4

-4.9

0.000

-7681.6

-135.2

0.011

3.10

UCHL1

7345

166

60

2780

0.000

776.3

15.3

0.000

7130.9

40.9

0.023

2.64

SCGB2A1

4246

508

12796

463

0.089

138.0

-1.2

0.000

-7051.1

-28.3

0.044

0.39

C10orf81

79949

67

1597

79

0.166

67.6

1.1

0.000

-6772.8

-22.0

0.021

2.93

GALNT10

55568

541

1348

415

0.001

-398.3

-1.3

0.000

-6755.1

-3.4

0.047

2.47

SCAMP4

113178

1624

3677

1732

0.232

-19.1

1.1

0.000

-6747.8

-2.2

0.049

0.43

PRKCI

5584

966

772

1785

0.000

578.1

1.8

0.000

6688.2

2.2

0.034

0.37

ARHGAP26

23092

869

1672

489

0.000

-503.3

-1.9

0.000

-6684.9

-3.6

0.018

2.89

ENPP3

5169

30

182

8

0.000

-595.1

-4.0

0.000

-6607.7

-23.0

0.028

2.96

SERPINA3

12

251

1909

88

0.000

-421.4

-2.7

0.000

-6472.2

-21.9

0.021

2.77

RNASE4

6038

2139

425

92

0.000

-943.0

-23.0

0.000

-6201.8

-4.8

0.029

2.65

TSPAN8

7103

92

220

20

0.000

-627.1

-5.0

0.000

-6184.5

-11.4

0.005

3.67

BMPR1B

658

411

1123

303

0.038

-204.2

-1.4

0.000

-6123.6

-4.0

0.041

2.44

TMEM62

80021

296

726

335

0.077

151.4

1.1

0.000

-6092.1

-2.3

0.017

0.34

FMO5

2330

77

67

17

0.000

-794.6

-4.7

0.000

-6046.9

-4.4

0.040

2.77

S100A1

6271

263

150

1206

0.000

619.1

4.1

0.000

6046.1

7.3

0.027

0.37

B4GALNT3

283358

213

947

336

0.001

401.0

1.6

0.000

-5990.9

-2.9

0.032

2.88

CSF3

1440

10

43

1

0.000

-458.1

-9.0

0.000

-5989.8

-38.1

0.009

3.53

SLC6A11

6538

9

0

16

0.023

241.1

1.7

0.000

5985.5 1.8E+09

0.022

2.62

SLC12A2

6558

740

871

407

0.000

-607.2

-1.9

0.000

-5768.3

-2.3

0.015

2.94

STEAP1

26872

108

229

58

0.001

-373.8

-1.9

0.000

-5696.1

-4.1

0.036

2.49

C4orf39

152756

35

6

29

0.115

-113.4

-1.2

0.000

5592.4

4.8

0.040

0.38

CCDC99

54908

154

218

506

0.000

860.7

2.9

0.000

5553.2

2.1

0.014

2.86

BEX2

84707

538

179

556

0.218

25.9

-1.0

0.000

5481.9

2.9

0.024

2.67

CD47

961

2037

1938

4377

0.000

496.6

2.0

0.000

5463.9

2.1

0.029

2.79

STEAP2

261729

755

363

108

0.000

-857.1

-7.0

0.000

-5376.7

-3.6

0.021

2.75

MOSC2

54996

169

187

99

0.000

-534.3

-1.8

0.000

-5336.0

-2.1

0.023

2.90

CCDC42B

387885

11

230

38

0.086

141.0

3.2

0.000

-5279.7

-6.6

0.019

0.35

MUC13

56667

23

284

19

0.198

-45.5

-1.3

0.000

-5212.0

-15.3

0.011

3.74

PODXL

5420

6115

5563

2386

0.000

-613.5

-2.8

0.000

-5195.2

-2.5

0.020

3.09

SCGB1D2

10647

101

877

106

0.085

143.0

-1.0

0.000

-5075.6

-8.8

0.021

0.34

SLC27A2

11001

16

145

51

0.061

171.1

3.0

0.000

-5074.7

-3.1

0.030

2.86

WASF1

8936

346

354

928

0.000

615.4

2.5

0.000

5003.2

2.4

0.045

2.43

LPAR1

1902

412

318

131

0.000

-746.6

-3.2

0.000

-4975.4

-2.5

0.016

3.25

TUBA4B

80086

MCC

4163

SYCE1L

37

278

63

0.239

8.7

1.6

0.000

-4858.2

-4.7

0.002

0.25

1102

439

165

0.000

-859.6

-7.4

0.000

-4771.6

-2.8

0.030

2.64

100130958

33

66

19

0.010

-280.8

-1.7

0.000

-4768.7

-3.6

0.050

2.38

GPX2

2877

10

88

5

0.192

-51.0

-1.9

0.000

-4759.5

-17.1

0.021

3.38

LRCH2

57631

348

16

65

0.000

-608.8

-5.8

0.000

4705.6

3.7

0.037

2.81
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ERG

2078

962

227

106

0.000

-570.8

-9.9

0.000

-4701.1

-2.3

0.044

2.43

PPP1R1B

84152

540

1619

404

0.202

-42.4

-1.5

0.000

-4661.8

-4.4

0.014

3.15

PARM1

25849

1908

502

158

0.000

-732.6

-12.8

0.000

-4655.4

-3.4

0.014

3.03

PIP5K1B

8395

136

137

50

0.000

-503.5

-2.8

0.000

-4591.2

-2.8

0.009

3.53

CEACAM5

1048

2

97

5
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Table 1. Differentially expressed genes between low-grade EEC and UPSC.
Genes are ranked by SAM score (UPSC vs low-grade EEC). SAM analysis was performed with level
3 raw counts from the RNA sequencing dataset. The SAM score (d) is the relative difference in gene
expression. Hazard ratio is the risk of patients with gene expression above the median divided by the
risk of patients with gene expression below the median.
q = q-value; d = SAM score; p = p-value; HR = hazard ratio.
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Median RSEM expression
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d
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Table 2. 19 candidate genes with higher expression in UPSC than in normal tissue and lowgrade EEC, and associated with poorer overall survival in UPSC patients.
Genes are ordered by median RSEM expression in UPSC patients. SAM analysis was performed with
level 3 raw counts from the RNA sequencing dataset. The SAM score (d) is the relative difference in
gene expression. Hazard ratio is the risk of patients with gene expression above the median divided
by the risk of patients with gene expression below the median.
q = q-value; d = SAM score; p = p-value; HR = hazard ratio.
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Figure 7. UCHL1 is upregulated in UPSC and correlates with poorer overall survival in the
TCGA data set.
(A) Heat map of the genes differentially expressed between UPSC and low grade EEC, with a
significant association with overall survival in UPSC patients.
(B) UCHL1 RNA expression across histological subtypes of endometrial cancer.
(C) UCHL1 RNA expression across EEC1 grades.
(D) UCHL1 RNA expression across UPSC stages.
(E) UCHL1 RNA expression across integrated molecular subtypes of endometrial cancer.
(F) Kaplan-Meier analysis of UCHL1 expression and overall survival.
Graphs represent median with interquartile range. N.S. = not significant; p = p-value.
*p<0.05, **p<0.01, ***p<0.001.
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Variable

Pts (n)

Events (n)

HR

95% CI

p

69

15

1.07

0.99-1.17

0.107

29
5
30
5

4
1
8
2

1.00
0.59
1.57
3.07

Reference
0.05-5.73
0.587
0.58-9.34
0.230
1.61-211.97
0.019a

55
24

10
5

1.00
0.88

Reference
0.23-3.44
0.855

36
33

6
9

1.00
3.24

Reference
1.01-10.44
0.049a

Age
Stage*
I
II
III
IV
Residual tumor*
R0
R1-R2
UCHL1 expression*
Below median
Above median

Table 3. Cox regression analysis of overall survival of UPSC patients.
Cases with missing information were excluded from analysis.
R0 = no residual tumor; R1 = microscopic residual tumor; R2 = macroscopic residual tumor; Pts =
patients; HR = hazard ratio; CI = confidence intervals; p = p-value; * = categorical variable; a =
statistically significant.

55

UCHL1 upregulation and correlation with shorter overall survival time is validated in
immunohistochemical staining of paraffin-embedded tumor samples

To validate the increased expression of UCHL1 in UPSC that we observed with the TCGA data
set, we performed immunohistochemical staining of UCHL1 in an independent cohort of UPSC,
ECC, and normal endometrial tissue paraffin-embedded samples. Normal samples were from a
mixture of pre- and postmenopausal individuals. Patient demographics are shown in Table 4. In
concordance with the TCGA data set, quantification of staining intensity showed that UCHL1
expression was significantly higher in pure and mixed UPSC than in normal tissue and ECC, and
there was no significant difference between mixed and pure UPSC (Figure 8 and 9A).
UCHL1 staining intensity was the lowest in normal endometrial tissue. In all normal
endometrial samples and the majority of grade 1 and 2 EEC, there was negative staining or a dotted
cytoplasmic staining pattern near the apical surface of the glandular cells. UCHL1 was also strongly
positive in the epithelial cells of normal ovarian tissue and in a small fraction of epithelial cells in the
normal fallopian tube. In contrast, the majority of UPSC tumors (42/50 pure UPSC samples)
exhibited a diffuse staining pattern in the carcinoma cells, with occasional nuclear staining. Age,
ethnicity, histological purity, and tumor stage were not significantly correlated with UCHL1
expression in the UPSC subset (Figure 9B and Table 5).
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Endometrioid (n=34)

Serous (n=74)

Total (n=108)

n (%)

n (%)

n (%)

Mean

64.2

68.5

67.2

SD

8.5

8.0

8.3

Median

63.0

69.0

67.0

Minimum

53.0

43.0

43.0

Maximum

83.0

85.0

85.0

25 (74)

45 (61)

70 (65)

African American

2 (6)

22 (30)

24 (22)

Hispanic

7 (21)

5 (7)

12 (11)

0

2 (3)

2 (2)

34 (100)

49 (66)

83 (77)

0

25 (34)

25 (23)

1

10 (29)

0

10 (9)

2

15 (44)

0

15 (14)

3

9 (27)

74 (100)

83 (77)

I

19 (56)

31 (42)

50 (46)

II

4 (12)

3 (4)

7 (7)

III

6 (18)

24 (32)

30 (28)

IV

5 (15)

16 (22)

21 (19)

31 (91)

20 (27)

51 (47)

Average (Mean ± 0.5 SD)

2 (6)

21 (28)

23 (21)

High (> Mean + 0.5 SD)

1 (3)

33 (45)

34 (32)

Eutrophic (18.50 - 24.99)

0

14 (19)

14 (13)

Overweight (25 - 29.99)

6 (18)

9 (12)

15 (14)

Obese (≥ 30)
Unknown

27 (79)
1 (3)

40 (54)
11 (15)

67 (62)
12 (11)

Parameter
Age, years

Ethnicity
Caucasian

Asian
Histology purity
Pure
Mixed
Grade

Stage

UCHL1 staining intensity
Low (< Mean - 0.5 SD)

2

BMI (kg/m )

Table 4. Demographic characteristics of patients in the immunohistochemical analysis of
UCHL1.
Mean and S.D. UCHL1 staining intensity was taken from all tumor samples. n = number of patients.
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Figure 8. Representative slides for UCHL1 staining in various gynecological tissues.
Scale bar, 100 µm
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Figure 9. UCHL1 upregulation in UPSC is validated in immunohistochemical staining of an
independent cohort of paraffin-embedded tumor samples.
(A) Quantified UCHL1 staining intensity across tissue types. 6 normal samples were from
premenopausal women (3 proliferative, 3 secretory), and 5 from postmenopausal women.
(B) UCHL1 staining intensity across stages of UPSC (pure/mixed).
Graphs represent median with interquartile range. N.S. = not significant.
*p<0.05, **p<0.01, ***p<0.001.
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Variable

p-value

Age

0.278

Ethnicity

0.142

Purity

0.771

Stage

0.145

Table 5. Association of clinical factors with UCHL1 staining intensity in UPSC paraffin
samples.
The Kruskal-Wallis test was used to test for difference in UCHL1 staining intensity across groups.
For age, patients were grouped by 10 year intervals. Graphs represent median with interquartile range.

There was no association between UCHL1 expression and survival when analyzing early stage
patients alone or all patients together. However, in the 24 late stage patients with no evidence of
disease after completion of treatment, high UCHL1 expression was significantly associated with
poorer disease-free survival (p=0.031) and overall survival (p=0.028) by univariate analysis (Figure
10A and B). The association between high UCHL1 expression and overall survival remained
significant with multivariate analysis, while a similar trend was seen for disease-free survival (Table
6). Overall, this suggests that UCHL1 affects the clinical outcome of late-stage UPSC patients rather
than early-stage patients.
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Figure 10. High UCHL1 staining intensity exhibits a trend towards poorer disease-free and
overall survival in late-stage UPSC patients.
Kaplan-Meier analysis of (A) disease-free and (B) overall survival of UPSC patients grouped above
and below the median UCHL1 staining intensity. Analysis is of late-stage UPSC patients with no
evidence of disease after treatment. Cases with missing survival data have been excluded.
p = p-value.
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Disease-free survival
Variable

Pts (n)

Events
HR
(n)

Overall survival

95% CI

p

Pts
(n)

Events
HR
(n)

0.90-1.07

0.636

24

15

1.01

19

12

1.00

95% CI

p

0.93-1.10

0.754

Age
Histology*
Pure UPSC
Mixed:
EEC/UPSC
Stage*
III
IV
UCHL1 expression*
Below median
Above median

23

11

0.98

18

9

1.00

6

2

1.05

0.958

5

3

0.60

0.15-2.51

15
9

6
5

1.00
Reference
3.23 0.78-13.39 0.105

15
9

8
7

1.00
3.70

Reference
1.05-12.98 0.041a

12
11

4
7

1.00
Reference
3.89 0.92-16.51 0.065

12
12

6
9

1.00
3.99

Reference
1.18-13.51 0.026a

Reference
0.20-5.56

Reference
0.487

Table 6. Cox regression analysis of late-stage UPSC patients with no evidence of disease after
treatment.
Cases with missing survival information were excluded from analysis.
Pts = patients; HR = hazard ratio; CI = confidence intervals; p = p-value; * = categorical variable; a =
statistically significant.
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Conclusion

In this chapter, we demonstrated that UPSC is genetically distinct from low-grade EEC but
shares some similarities with grade 3 EEC. By performing SAM analysis to compare the RNA
expression profiles of UPSC vs. low-grade EEC and UPSC vs. normal endometrial tissue, we found
UCHL1 expression to be significantly higher in UPSC than both low-grade EEC and normal
endometrium; high expression was also associated with poorer overall survival. This was validated by
immunohistochemical staining of an independent cohort of patient samples, where high UCHL1
staining intensity was associated with poorer disease-free and overall survival in late-stage patients by
univariate analysis, and with poorer overall survival by multivariate analysis. Taken together, this
suggests that UCHL1 has an oncogenic role in UPSC.
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CHAPTER 4:
UCHL1 PROMOTES TUMOR CELL PROLIFERATION IN UPSC
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Specific Aim 2. To delineate the functional role of UCHL1 in UPSC tumor progression.

UCHL1 is a deubiquitinating enzyme in the family of ubiquitin carboxyl-terminal hydrolases
and is primarily located in the cytoplasm, with possible transient localization to the nucleus [112].
Both oncogenic and tumor suppressive functions have been described for UCHL1 in a variety of
cancer types. Transgenic mice overexpressing UCHL1 under a ubiquitous promoter developed
spontaneous lipomas, lymphomas and lung adenomas [132]. Further studies using immortalized
human B-cell lines showed that UCHL1 promoted cell proliferation and survival. UCHL1 has also
been implicated in cell invasion and motility in lung, colorectal and prostate cancer cells [140, 141],
as well as epithelial-to-mesenchymal transition in prostate cancer [142].
On the other hand, silencing of UCHL1 has been reported in breast carcinoma cell lines
compared to normal breast tissue and mammary epithelial cells [143], nasopharyngeal carcinoma
cells [124] and in human prostate cancer samples [127]. Reintroduction of UCHL1 suppressed colony
formation and proliferation through G0/G1 cell cycle arrest and apoptosis in breast carcinoma cell
lines [143]; induced apoptosis in nasopharyngeal cell lines [124]; and reduced proliferation and
anchorage-independent growth in prostate cancer cells [127].
The functional role of UCHL1 in endometrial cancer remains unknown. Upregulation of
UCHL1 in UPSC compared to normal tissue and an association with worse prognosis indicate an
oncogenic function; we therefore sought to determine how its expression contributed to UPSC
aggressiveness.

siRNA-mediated silencing of UCHL1 reduces proliferation of UPSC cell lines in vitro

To determine the role of UCHL1 in UPSC progression in vitro, UCHL1 expression was first
measured in a panel of type I and II endometrial cell lines. UCHL1 RNA and protein expression was
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detected in all type II cell lines except ACI-158, as well as in poorly differentiated MFE-280 and the
moderately differentiated MFE-296 cell line of unknown histological origin (Figure 11A and B). All
type II cell lines were TP53-mutants (Figure 12), similar to the observation of TP53 mutation in the
majority of UPSC tumors. On the other hand, cell lines derived from type I endometrial tumors did
not show any detectable UCHL1.

Figure 11. UCHL1 is expressed in type II endometrial cancer cell lines.
(A) Quantification of UCHL1 RNA expression in endometrial cancer cell lines by qRT-PCR.
(B) Western blot analysis of UCHL1 protein expression in endometrial cancer cell lines.
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Figure 12. All type II endometrial cancer cell lines are TP53-mutant.

Using UPSC cell lines ARK1 and ARK2, the effect of UCHL1 silencing on apoptosis,
migration and proliferation was determined. Significant knockdown of UCHL1 was achieved at 72
hours after siRNA transduction (Figure 13).

Figure 13. Silencing of UCHL1 in ARK1 cells following transfection with UCHL1 siRNA.
N = control siRNA; 1 = UCHL1 siRNA #1; 2 = UCHL1 siRNA #3
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We did not observe any significant change in apoptosis (Figure 14) or migration following
UCHL1 silencing (Figure 15). In addition, sensitivity to paclitaxel and cisplatin was not increased in
UCHL1-silenced cells (Figure 16). However, we did observe by the MTT assay a significant
reduction in the growth rate of cells transfected with UCHL1 siRNA compared to those transfected
with control siRNA (Figure 17A). On the other hand, siRNA transfection in the UCHL1-negative
ACI-158 UPSC cell line did not significantly affect cell proliferation (Figure 17B). These results
suggest that UCHL1 expression increases the cell proliferation of UPSC tumor cells in vitro.
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Figure 14. UCHL1 knockdown does not affect apoptosis in ARK cells.
Apoptosis was measured four days after tranfection with control or UCHL1-silencing siRNA by
labelling with annexin V Alexa Fluor 488 and propidium iodide.
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Figure 15. UCHL1 knockdown does not affect migration of ARK1 and ARK2 cells.
Four days after siRNA transfection, equal numbers of ARK1 and ARK2 cells were seeded onto 8 µm
transwell inserts. 24 hours later, migrated cells were visualized by crystal violet staining.
Scale bar, 500 µm.
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Figure 16. UCHL1 expression does not increase tumor cell resistance to paclitaxel or cisplatin
in vitro.
Following siRNA-mediated knockdown of UCHL1, ARK1 and ARK2 cells were treated with
paclitaxel or cisplatin for three days before cell growth measurement by MTT assay.
(A) Dose-response curve for paclitaxel treatment.
(B) Dose-response curve for cisplatin treatment.
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Figure 17. UCHL1 knockdown reduces UPSC cell proliferation in vitro.
Effect of UCHL1 knockdown on cell proliferation of (A) the UCHL1-positive ARK1 and ARK2 cells
and (B) UCHL1-negative ACI-158 cells in vitro, as measured by the MTT assay.
Graph represents mean ± SD. *p<0.05, **p<0.01, ***p<0.001.
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Doxycyline-inducible shRNA-mediated silencing of UCHL1 reduced tumor growth in vivo

To determine whether UCHL1 stimulates UPSC cell proliferation in vivo, we utilized
luciferase-labelled ARK1 cells transduced with doxycycline-inducible control shRNA (ARK1-lucdox-shNT) or anti-UCHL1 shRNA (ARK1-luc-dox-shUCHL1). Successful doxycycline-induced
silencing of UCHL1 was first confirmed in vitro (Figure 18).

Figure 18. Doxycyline-induced UCHL1 knockdown in ARK1 cells.
Cells were cultured in medium with 2µg/ml doxycycline.

Control cells and knockdown cells were injected intraperitoneally into two groups of nude
mice, which were then switched to a doxycycline diet (Figure 19A), followed by measurement of in
vivo bioluminescence every two weeks. By week ten, the control group had significantly higher
luciferase activity (Figures 19B and 19C), suggesting that UCHL1 contributes to tumor growth in
vivo. We also observed a trend towards improved overall survival in mice injected with ARK1-lucdox-shUCHL1 (Figure 19D).
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Figure 19. UCHL1 knockdown reduces UPSC cell proliferation in vivo.
(A) Luciferase-labelled ARK1 cells transduced with doxycycline-inducible control shRNA or antiUCHL1 shRNA were injected intraperitoneally into nude mice; mice were then switched to a
doxycycline diet (625 mg/kg).
(B) Representative images of in vivo bioluminescence imaging at week 10. Mice with bioluminescent
intensities nearest to the mean are shown.
(C) Geometric mean of the fold change in in vivo bioluminescence intensity relative to week 2.
Standard deviation was calculated from log2 fold change and converted back to linear values.
The Mann-Whitney test was used to test for significant differences between log2 fold changes. Graph
represents mean ± SD.
(D) Kaplan-Meier survival curves of nude mice injected with ARK1 cells transduced with
doxycycline-inducible control shRNA or anti-UCHL1 shRNA.
p = p-value. *p<0.05, **p<0.01, ***p<0.001.

LDN-57444 treatment in vivo reduces tumor growth and improves overall survival

As UCHL1 promotes tumorigenesis of UPSC, we sought to determine if suppressing UCHL1
activity by UCHL1 inhibitors would reduce tumor growth and improve survival. To do so, we again
established UPSC tumors in vivo and treated the mice thrice weekly with intraperitoneal injection of
the small-molecule UCHL1 inhibitor, LDN-57444 [261] (Figure 20A). There was no significant drop
in body weight, suggesting a lack of systemic toxicity (Figure 20B). By week 6, the treatment group
had significantly lower bioluminescence than the control group, indicating that LDN-57444 treatment
had an anti-proliferative effect on ARK1 cells in vivo (Figure 20C-E). Furthermore, the treatment
group showed improved overall survival, with a mean survival time of 68.1 days compared to 56.9
days for the control group (Figure 20F). These results suggest that targeting of UCHL1 would aid in
the management of UPSC.
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Figure 20. LDN-57444 exhibits anti-proliferative effect in vivo.
(A) Luciferase-labelled ARK1 cells were injected intraperitoneally into nude mice; after 2 weeks,
mice were treated thrice weekly with PBS control or LDN-57444.
(B) Mouse weights of nude mice following treatment with PBS control (0.5% DMSO, 2.5% ethanol)
or 0.5 mg/kg LDN-57444.
(C) Representative images of in vivo bioluminescence imaging at week 6. Mice with bioluminescent
intensities nearest to the mean are shown.
(D) In vivo bioluminescence of tumors at week 2, 4 and 6.
(E) Geometric mean of the fold change in in vivo bioluminescence intensity relative to week 2.
Standard deviation was calculated from log2 fold change and converted back to linear values.
The Mann-Whitney test was used to test for significant differences between log2 fold changes.
(F) Kaplan-Meier survival curves of the LDN-57444 treatment group and control group.
Graphs represent mean ± SD. p = p-value. *p<0.05, **p<0.01, ***p<0.001.

Conclusion

In this chapter, we demonstrated that UCHL1 is expressed in type II and poorly differentiated
endometrial cell lines. UCHL1 knockdown did not affect apoptosis or migration, or increase
sensitivity to paclitaxel or cisplatin. However, UCHL1 silencing reduced cell proliferation in vitro
and tumor growth in vivo. In addition, inhibition of UCHL1 in vivo by the UCHL1-specific smallmolecule inhibitor LDN-57444 reduced tumor growth and improved overall survival in nude mice.
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CHAPTER 5:
UCHL1 PROMOTES CYCLIN B1 PROTEIN STABILITY
AND CELL CYCLE PROGRESSION
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Specific Aim 3. To determine the mechanisms through which UCHL1 modulates UPSC tumor
progression.

UCHL1 has been reported to interact with a variety of targets in different cancer types. As a
deubiquitinating enzyme with reported dual ubiquitin hydrolase/ligase function [106], UCHL1 has
been shown to interact with and affect the stability of various proteins. UCHl1 interacts with JAB1 in
lung cancer cells, resulting in nuclear translocation and promotion of p27 degradation [112]. In
nasopharyngeal cancer cells, UCHL1 forms a complex with p53, p14ARF and MDM2, promoting
degradation of MDM2 and stabilization of p53/p14ARF [124]. In colorectal cancer, UCHL1 carries out
its oncogenic function by stabilizing β-catenin through its deubiquitinating activity [150]. UCHl1 also
interacts with and enhances the kinase activity of the cyclin-dependent kinases 1, 4 and 5 to increase
cell proliferation, independent of its deubiquitinating function [147].
In spite of this, the mechanism through which UCHL1 affects tumor progression of UPSC
remains unknown. We therefore sought to identify its downstream targets.

Correlation of UCHL1 RNA expression with proteins in the RPPA data set

To determine potential downstream targets of UCHL1 that mediate the effect of UCHL1 in
UPSC progression, we identified genes whose protein expression levels correlated with UCHL1 RNA
expression in the TCGA data. As UCHL1 is a deubiquitinating enzyme, of particular interest were the
genes whose expression was associated with UCHL1 expression at the protein level but not at the
RNA level, as they were more likely to be direct targets (Figure 21).
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Figure 21. Discovery of potential protein targets of UCHL1.

Using the 22 pure UPSC samples with both RPPA and RNA sequencing data available,
Spearman’s test of correlation was performed for each protein probe to measure its strength of
correlation with UCHL1 RNA expression. Of 166 probes, 17 proteins were significantly correlated at
the protein level (Table 7). Of these, 10 were not correlated at the RNA level with UCHL1
expression. 6 of the 10 proteins (cyclin B1, p21, GSK3α, GSK3β, MSH2, RAD50) were positively
correlated with UCHL1 expression at the protein level, suggesting that their protein stability may be
increased by the deubiquitinating activity of UCHL1.
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UCHL1 vs RPPA
Entrez ID Gene

Protein

840

Caspase 7

CASP7

Spearman's
coefficient

p

-0.54

UCHL1 vs RNAseq
Spearman's
coefficient

p

0.010a

-0.19

.393

a

-0.34

.120

841

CASP8

Caspase 8

-0.44

0.039

891

CCNB1

Cyclin B1

0.43

0.044a

0.31

.164

a

-0.12

.601

1026

CDKN1A

p21

0.43

0.045

2931

GSK3A

GSK3α

0.55

0.008a

-0.07

.759

a

0.09

.687

2932

GSK3B

GSK3β

0.55

0.008

3485

IGFBP2

IGFBP2

0.45

0.036a

0.50

.018a

8821

INPP4B

INPP4B

-0.50

0.017a

-0.63

.002a

3725

JUN

c-Jun

0.51

0.015a

0.60

.003a

3932

LCK

LCK

-0.47

0.028a

-0.55

.009a

4233

MET

c-Met

-0.58

0.005a

-0.49

.020a

4436

MSH2

MSH2

0.59

0.004a

0.14

.533

a

0.45

.035a

2956

MSH6

MSH6

0.56

0.006

57111

RAB25

RAB25

-0.60

0.003a

0.06

.805

a

-0.18

.417

10111

RAD50

RAD50

0.45

0.035

7408

VASP

VASP

-0.46

0.030a

-0.63

.002a

7515

XRCC1

XRCC1

-0.42

0.049a

0.15

.503

Table 7. Proteins significantly correlated with UCHL1 RNA expression in the TCGA dataset.
Genes from the RPPA dataset were analyzed by Spearman’s correlation to identify proteins
significantly correlated with UCHL1 RNA expression in 22 pure UPSC samples. RNA expression
data was extracted for significant genes and correlation analysis was again performed against UCHL1
RNA expression.
p = p-value; a = statistically significant.
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UCHL1 upregulates cyclin B1 protein expression

While MSH2 and RAD50 are involved in DNA mismatch repair [262] and double-strand
break repair [263, 264] respectively, cyclin B1, p21, GSK3α and GSK3β are directly involved in
pathways that dictate cell proliferation [153, 154, 265, 266]. These four proteins were therefore of
particular interest, as our primary observation was an effect of UCHL1 on UPSC proliferation.
UCHL1 has also been reported to affect the protein stability of cell cycle-related proteins p27 [112],
p53 [124] and β-catenin [150]. Although these were not significantly correlated with UCHL1 in the
TCGA RPPA dataset, we also sought to determine if UCHL1 increased p53 and β-catenin proteins
levels or reduced p27 protein levels in vitro as previously described.
Following siRNA-mediated silencing of UCHL1, we could not observe a consistent decrease
in p21, GSK3α or GSK3β protein level (Figure 22). We also did not see a change in p53 or β-catenin
protein by western blot after UCHL1 silencing; the change in p27 levels was not consistent across the
two cell lines. In contrast, siRNA-mediated silencing of UCHL1 led a reduction in cyclin B1 levels in
ARK1, ARK2 and HEC-50 cells compared with cells transfected with control siRNA (Figure 23A).
Cyclin D1 and cyclin E levels were largely unchanged. In addition, the RNA level of cyclin B1 after
transfection was not significantly lower than cells transfected with control siRNA (Figure 23B),
suggesting that the reduction in cyclin B1 protein level was due to changes in protein stability and not
due to reduced RNA transcription. Conversely, transient expression of UCHL1 in UCHL1-negative
ACI-158 cells led to increased protein levels of cyclin B1 (Figure 23C). Cyclin B1 was therefore of
particular interest, due to its role as a positive regulator of cell cycle progression that could potentially
mediate the effects of UCHL1 on increased cell proliferation.
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Figure 22. The effect of UCHL1 silencing on the protein levels of genes involved in cell cycle and
proliferation.
Western blot was performed four days after transfection with control or anti-UCHL1 siRNA in ARK1
and ARK2 cells.
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Figure 23. UCHL1 upregulates cyclin B1 protein expression in vitro.
(A) Expression of cyclin proteins four days after transfection with control or anti-UCHL1 siRNA in
ARK1, ARK2 and HEC-50 cells.
(B) qRT-PCR quantification of cyclin B1 four days after siRNA-mediated UCHL1 silencing. Graph
represents mean ± SD. *p<0.05, **p<0.01, ***p<0.001.
(C) Cyclin B1 expression following transient UCHL1 overexpression in ACI-158 cells.
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Cyclin B1 is a positive regulator of cell cycle progression that could potentially mediate the
effects of UCHL1 on increased cell proliferation. In comparison, protein expression of the other
cyclins in the TCGA RPPA data set, cyclin D1 and E1, were not correlated with UCHL1 expression
patients with UPSC (Table 8). Similar to UCHL1, cyclin B1 protein expression was significantly
higher in UPSC and grade 3 EEC than in low-grade EEC in the TCGA data set (Figure 24).

Cyclin B1

Cyclin D1

Cyclin E1

Histology

Pts
(n)

Spearman's
coefficient

p

Spearman's
coefficient

p

Spearman's
coefficient

p

All EC

196

0.334

<0.001a

-0.037

0.603

0.333

<0.001 a

EEC

171

0.255

<0.001a

-0.065

0.401

0.291

<0.001 a

Pure UPSC

22

0.433

0.044 a

0.163

0.468

-0.137

0.543

Table 8. Protein expression of cyclin proteins against UCHL1 RNA expression.
Cyclin B, D and E protein expression in the TCGA RPPA dataset were correlated with UCHL1 RNA
expression.
Pts = patients; p = p-value; a = statistically significant.
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Figure 24. Cyclin B1 protein expression across histological subtypes of endometrial cancer.
Graph represents median with interquartile range. *p<0.05, **p<0.01, ***p<0.001.

To validate the correlation of UCHL1 with cyclin B1 protein levels that we observed in the TCGA
data set, we performed immunohistochemical staining of cyclin B1 in the UPSC samples that were
previously stained for UCHL1. The results showed a significant positive correlation between
percentage of tumor cells positive for cyclin B1 and UCHL1 staining intensity (p=0.009) (Figure 25A
& B).
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Figure 25. Cyclin B1 positivity correlates with UCHL1 staining intensity.
(A) Correlation between cyclin B1 positivity and UCHL1 staining intensity in the UPSC cohort.
(B) Representative slides of samples stained for both cyclin B1 and UCHL1 with increasing
semiquantitative score. Scale bar, 100 µm.
Graph represents mean ± SD.
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To confirm that UCHL1 upregulates cyclin B1 protein expression in vivo,
immunohistochemical staining of cyclin B1 was performed in the doxycycline-induced control and
UCHL1-silenced tumors from our previous mouse study. The results showed that cyclin B1 positivity
was reduced in the tumors established from ARK1 cells transduced with doxycycline-inducible
UCHL1 shRNA compared to control shRNA (Figure 26A and B), suggesting that UCHL1
upregulates cyclin B1 protein expression in vivo.

Figure 26. UCHL1 upregulates cyclin B1 protein expression in vivo.
(A) Cyclin B1 and UCHL1 staining in tumors that developed following intraperitoneal injection of
nude mice with ARK1 cells transduced with doxycycline-inducible control shRNA or anti-UCHL1
shRNA. Scale bar, 100 µm.
(B) Percentage positivity of cyclin B1 in tumor cells at time of sacrifice.
Graph represents mean ± SD. *p<0.05, **p<0.01, ***p<0.001.
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UCHL1 interacts with cyclin B1

To delineate the molecular mechanism by which UCHL1 regulates cyclin B1 expression, we
first determined whether UCHL1 interacts with cyclin B1 in a protein complex, which is essential for
UCHL1 to exert its effect on cyclin B1. To determine if UCHL1 interacted with cyclin B1, coimmunoprecipitation was performed with pull-down of UCHL1 and cyclin B1, which indicated
protein-protein interaction between UCHL1 and cyclin B1 (Figure 27).

Figure 27. Protein interaction between UCHL1 and cyclin B1 is confirmed by coimmunoprecipitation.
Co-immunoprecipitation was performed using antibodies against UCHL1 and cyclin B1, with normal
mouse IgG as a control.

Furthermore, through immunofluorescence imaging UCHL1 and cyclin B1 were shown to
colocalize (Figure 28). This was additionally supported by the proximity ligation assay, which
revealed red fluorescent spots in ARK1 and ARK2 cells but not UCHL1-negative HEC-1A cells upon
co-incubation with anti-UCHL1 and anti-cyclin B1 antibody, indicating an interaction between the
two proteins. Additionally, the number of red fluorescent spots observed was considerably lower
when ARK1 cells were assayed without primary antibody, with anti-UCHL1 antibody only, or with
anti-MMP-13 and anti-cyclin B1 together, as we did not anticipate MMP-13 and cyclin B1 to interact
with each other. Similar results were seen with ARK2 probed with anti-UCHL1 antibody only.
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Figure 28. UCHL1 and cyclin B1 colocalize and interact in vitro.
Immunofluorescence staining and the Duolink proximity ligation assay was performed on ARK1 and
ARK2 cells. As a control, ARK1 cells were also stained without primary antibody, with anti-UCHL1
antibody only, and with anti-MMP-13 and anti-cyclin B1. ARK2 cells were also stained with antiUCHL1 antibody only; staining of UCHL1-negative HEC-1A cells was also performed. Scale bar, 50
µM.

As previously discussed, in the immunohistochemical analysis of our UPSC patient cohort,
we observed strong cytoplasmic staining and occasional nuclear staining of UCHL1. Similarly,
immunofluorescence showed that UCHL1 was expressed in both the cytoplasm and nucleus of ARK1
and ARK2 cells (Figure 28). On the other hand, the variation in cyclin B1 expression and localization
was more pronounced, with expression observed in the cytoplasm of some cells and in the nucleus in
others. Immunofluorescence of ARK1 cells undergoing mitosis indicated that cyclin B1 entered the
nuclear space during late interphase (Figure 29); colocalization of UCHL1 and cyclin B1 then
persisted through mitosis until degradation of cyclin B1 at the metaphase-anaphase transition.
Therefore, the majority of fluorescent spots were in the cytoplasm; however, when cyclin B1 entered
the nucleus, interaction between the two proteins was also observed.
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Figure 29. UCHL1 and cyclin B1 interact during interphase and mitosis.
ARK1 cells were synchronized by double thymidine block, then collected 10 hours after release to
enrich for mitotic cells. Scale bar, 10 µM.

UCHL1 silencing by siRNA transduction abrogated the fluorescent signal. (Figure 30).
Overall, these results suggest that UCHL1 and cyclin B1 are in close proximity and interact with each
other in all phases of the cell cycle where cyclin B1 is present.

Figure 30. UCHL1 silencing by siRNA transduction abrogates the fluorescent signal
representing UCHL1-cyclin B1 interaction.
Immunofluorescence staining and the Duolink proximity ligation assay was performed on ARK1 cells
4 days after transfection with control siRNA or anti-UCHL1 siRNA. Following the Duolink assay,
red fluorescent spots indicate presence of protein-protein interaction. Scale bar, 50 µM.
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UCHL1 increases protein stability of cyclin B1

Since UCHL1 has been shown to affect the protein stability of target proteins in other cancer
types by altering their ubiquitination [124, 150, 152], we next sought to establish whether UCHL1
directly affected the protein stability of cyclin B1. Cycloheximide chase assay showed a reduction in
cyclin B1 protein half-life in ARK1 and ARK2 cells transfected with anti-UCHL1 siRNA compared
to control siRNA (Figure 31), suggesting that UCHL1 increases the stability of cyclin B1 protein and
impedes its degradation.

Figure 31. UCHL1 silencing reduces cyclin B1 protein half-life.
Cycloheximide (CHX) chase assay of cyclin B1 was performed in ARK1 and ARK2 cells 4 days after
transfection with UCHL1 siRNA. Protein lysate was collected at the indicated time points after the
addition of CHX.
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To further determine whether ubiquitination plays a role in mediating the effect of UCHL1 on
cyclin B1 stabilization, we evaluated the ubiquitination of cyclin B1 in UCHL1 silenced ARK1 cells.
As cyclin B1 may be targeted for degradation by the anaphase-promoting complex via K48ubiquitination, K11-ubiquitination or multiple monoubiquitination [181, 182], we chose to detect total
ubiquitin levels after immunoprecipitation of cyclin B1. The results showed an increase in
ubiquitination of cyclin B1 in UCHL1-silenced cells as revealed by Western blot analysis (Figure 32).
Together, these results suggest that UCHL1 stabilizes protein levels of cyclin B1 by reducing its
ubiquitination and subsequently impairing its degradation.
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Figure 32. UCHL1 modulates cyclin B1 protein stability by deubiquitination.
Ubuiquitination of cyclin B1 in ARK1 and ARK2 cells was evaluated 4 days after siRNA
transfection. Cells were pretreated 25 μg/ml MG132 for 4 hours before protein extraction. Ubiquitin
staining was quantified with ImageJ and normalized to cyclin B1 staining following
immunoprecipitation (IP: CCNB1, WB: CCNB1). Degree of ubiquitination is shown relative to cells
transfected with control siRNA.
IP = immunoprecipitation; WCL = whole cell lysate; WB = western blot; Ub1 = monoubiquitin;
Ubn = multiple ubiquitin conjugates; IgG = heavy antibody chain.
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UCHL1 promotes cell cycle progression

Since UCHL1 can up-regulate cyclin B1 protein expression and cyclin B1 is essential for
cells to enter mitosis, we sought to determine the effect of UCHL1 on cell cycle progression in UPSC
cells. ARK1 cells transfected with UCHL1 siRNA or control siRNA were synchronized in early G1
by serum starvation for 24 hours. After reintroduction of serum, cells were collected at 0h, 6h and 24h
and subjected to cell cycle analysis by flow cytometry. Knockdown cells progressed slower through
the cell cycle compared to control cells (Figure 33A). In particular, the percentage of control cells in
G2/M increased 17.4% from 0h to 24h, whereas cells transduced with shRNA 1 and 2 increased 3.9%
and 12.2% respectively, suggesting that UCHL1 affects cell cycle progression through its effect on
cyclin B1 protein levels. Inhibition of UCHL1 by LDN-57444 following synchronization at G1 by
serum starvation also indicated a drop in cyclin B1 levels by 23 hours after release from
synchronization (Figure 33B). Taken together, our results demonstrate that high levels of UCHL1 in
UPSC stabilizes cyclin B1 by reducing its ubiquitination and preventing its degradation, which
subsequently promotes mitotic entry.
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Figure 33. UCHL1 promotes cell cycle progression through stabilization of cyclin B1.
(A) ARK1 cells transfected with control or anti-UCHL1 siRNA were serum starved for 24-hours
before release into medium with 10% FBS; cells were collected for flow cytometry analysis at the
indicated time points.
(B) ARK1 and ARK2 cells were serum-starved for 24-hours before release into medium with 10%
FBS and 50 µM LDN-57444. Protein lysate was collected at indicated time points to measure cyclin
B1 levels.
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Conclusion

In this chapter, we demonstrated that cyclin B1 protein levels correlated positively with
UCHL1 RNA expression in the TCGA data set. This was validated in our independent cohort of
patient samples, where the percentage of tumor cells positive for cyclin B1 correlated with UCHL1
staining intensity. In ARK1 and ARK2 cells, knockdown of UCHL1 decreased cyclin B1 protein
levels, while transient expression in ACI-158 increased cyclin B1 protein levels. Percentage cyclin B1
positivity was also reduced in vivo in UCHL1-silenced tumors. Protein interaction between UCHL1
and cyclin B1 was confirmed by co-immunoprecipitation, immunofluorescence, and proximity
ligation assay. The UCHL1-cyclin B1 complex was detected both in the cytoplasm and in the nucleus
in early mitosis. UCHL1 was shown to promote protein stability and prolong the protein half-life of
cyclin B1 by deubiquitination, consequently promoting mitotic entry and cell cycle progression.
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CHAPTER 6:
DISCUSSION
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Due to the rarity of UPSC, information is lacking regarding optimal treatment and prognosis.
In addition, no targeted therapies are currently approved for UPSC, and there are limited candidate
targets. Therefore, the aim of this dissertation was to identify novel therapeutic targets using the
substantial number of cases found in The Cancer Genome Atlas (TCGA) database, containing 91 pure
UPSC samples with RNA sequencing data at time of download. We first utilized a purpose-driven
approach to identify genes contributing to tumor progression of UPSC. After we determined UCHL1
to have a potentially oncogenic role in UPSC, we began our hypothesis-driven approach to study its
role in UPSC tumorigenesis.

The genomic landscape of UPSC

It is known that the pathogenesis and genetic profile of UPSC is distinct from that of
endometrioid carcinomas. A previous study by Risinger et al. performed multidimensional scaling
using the RNA expression profiles of tumor samples as measured by cDNA microarray [267], which
confirmed that EEC, UPSC and CC tumors formed distinct clusters. However, this was a small study
of 7 age-matched normal endometrial samples and 19 EEC, 13 UPSC, and 3 CC tumors. In addition,
there was no distinction made between low-grade and grade 3 EEC, which are categorized into the
type I and type II groups respectively, due to the differences in clinical aggressiveness [268]. We
therefore sought to further examine the relationship between tumor subtypes using the larger TCGA
dataset.
Through principal component analysis of a larger group of samples in the TCGA dataset, we
observed the clustering of grade 1 and 2 EEC together, reflecting their close similarities. We also
observed a large variation within the normal tissue samples, with significant overlap with the EEC
clusters. This could be due to two possibilities. Firstly, being the tumor subtype with the best
prognosis and the least genetic aberrations, they are expected to be genetically closest to normal
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samples. Secondly, as these were paired samples obtained from uterine tissue adjacent to tumor and
verified by histology to be normal, this suggests that some normal tissue may already undergo genetic
changes prior to the development of hyperplasia or malignant histology. Therefore, adjacent tissue
may not be the best comparison for tumors.
On the other hand, mixed and pure UPSC samples were furthest away from normal samples,
reflecting their increased tumor aggressiveness and high frequency of copy-number alterations. The
grade 3 EEC cluster overlapped with both low grade EEC and UPSC, supporting the notion that there
are certain similarities between grade 3 EEC and UPSC at the RNA level. Zannoni et al. concluded
that grade 3 EEC was an intermediate group between low-grade EEC and other type II tumors, in
terms of clinical features such as local invasion, lymph node positivity and extra-uterine spread, and
histological features such as p53 mutation frequency, and ER, PR and Ki67 positivity [269]. In
addition, the clustering of endometrial tumors by The Cancer Genome Atlas Network [72], based on
mRNA expression profiles, also revealed that 56% of the grade 3 EEC samples clustered with the
majority of UPSC tumors in the mitotic group.
The survival outcomes of grade 3 EEC and UPSC have also been compared to each other.
The largest study comparing survival outcomes of 2316 grade 3 EEC and 1473 UPSC patients
indicated significantly poorer survival in UPSC at each stage [68], suggesting that grade 3
endometrioid carcinoma is of intermediate risk between grade 1 and 2 endometrioid carcinomas and
non-endometrioid carcinomas.

Identification of UPSC-promoting genes

With grade 3 EEC exhibiting molecular similarities with UPSC and an intermediate
aggressiveness between low-grade and UPSC, we chose to compare the RNA expression profile of
UPSC with low-grade EEC to discover differentially expressed genes. By filtering for genes with
significantly higher expression in UPSC compared to both normal endometrium and low-grade EEC,
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and which correlated with poorer overall survival, we derived a list of 19 genes with possible
oncogenic function. Although we filtered the genes prior to analysis to remove genes with a mean raw
count below 0.5 or 10 or less reads across all samples, 6 of the 19 genes had a median expression
below 10 for all three groups (normal, low-grade EEC, UPSC) and an extremely high fold change as
calculate by the SAM analysis. These genes were effectively ignored, as low-expressing genes have a
low signal-to-noise ratio and are therefore commonly unreliably deemed significant in analysis of
microarray and RNA sequencing data [270]. Excluding these 6 genes and UCHL1, which will be
discussed later, the list of candidate genes and known roles in cancer will be discussed.

WASF1
Wiskott-Aldrich syndrome protein family member 1 (WASF1) interacts with the actin-related
protein (Arp) 2/3 complex to form an actin nucleation site, initiating actin polymerization [271].
While WASF1 is non-essential for lamellipodia formation, it is instead involved in dorsal ruffle
formation [272], which in turn modulates cell motility and internalization of extracellular material
and membrane proteins [273]. Normal expression of WASF1 is mainly restricted to the brain [274],
but its overexpression has been associated with aggressive disease in ovarian carcinoma [275] due to
its effect on tumor cell migration and invasion, adhesion, colony formation and proliferation [276].
WASF1 overexpression has also been reported in prostate cancer, where it was involved in cell
invasion and proliferation [277].

CCDC99
Coiled-coil domain-containing protein 99 (CCDC99) was initially discovered to be an
essential recruiter of dynein to kinetochores in early mitosis before kinetochore-microtubule
attachment [278]. CCDC99 is therefore is involved in overcoming the spindle-assembly checkpoint,
as dynein is required for the removal of spindle-assembly checkpoint proteins from the kinetochore as
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they become correctly aligned, thus allowing cells to overcome the checkpoint and proceed to
anaphase. Loss of CCDC99 leads to chromosome misalignment and metaphase arrest [278, 279].
CCDC99 overexpression has been observed in lung cancer cell lines, where silencing of
CCDC99 enhanced the cytotoxic activity of paclitaxel by increasing the length of mitotic arrest [279].
Paclitaxel targets the microtubules to prevent deactivation of the spindle-assembly checkpoint; the
subsequent induction of prolonged arrest leads to apoptosis [280-282]. However, cancer cells can
escape by mitotic slippage due to compensatory mechanisms such as premature degradation of cyclin
B1 [283]. Targeting CCDC99 may therefore be a viable method to increase the cytotoxic effects of
paclitaxel before mitotic slippage occurs. Recent reports indicate that farnesylation of CCDC99 by
farnesyltransferase is required for its localization to the kinetochore, and treatment with
farnesyltransferase inhibitors FTI-277 and L-744-832 in vitro led to a phenotype similar to cells with
CCDC99 silencing [284, 285], providing a possible method of CCDC99 inhibition. The
farnesyltransferase inhibitor Lonafarnib is currently being evaluated in a phase II trial for patients
infected with the hepatitis delta virus [286].

PLXNA4
Plexin-A4 (PLXNA4) is a transmembrane receptor for the class-3 and -6 semaphorins
SEMA3A, SEMA6A and SEMA6B, which were originally discovered as axon guidance factors in the
central nervous system [287-289]. In HUVEC endothelial cells, PLXNA4 was found to mediate the
effects of semaphorins on the actin cytoskeleton and cell morphology [290]. PLXNA4 also affects
cancer cell function independent of its role in cytoskeletal organization, as it is able to complex with
FGFR1, FGFR2 and VEGFR2 to enhance bFGF and VEGF signaling. Accordingly, PLXNA4
inhibition in U87MG glioblastoma cells and A549 lung cancer cells resulted in reduced cell
proliferation in vitro and impaired tumor forming ability in vivo [290]. In addition, amplification of
PLXNA4 has been observed in melanoma and lung tumors [291], suggesting an oncogenic function in
cancer.
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COL9A1
Collagen type IX alpha 1 chain (COL9A1) is an extracellular protein and a component of
collagen that is preferentially expressed in chondrocytes [292, 293]. Hypomethylation of COL9A1 has
been observed in breast cancer [294], and its expression is associated with stem-like prostate cancer
cells [295], suggesting an oncogenic role in cancer. In addition, COL9A1 expression was reported in
a high-grade, serous-like cluster of ovarian, fallopian tube and peritoneal advanced serous cancers
[296]. In normal endometrial stromal cells, COL9A1 expression was reported to increase upon
estrogen stimulation [297].

FAM167A (aka C8orf13)
Little is known about family with sequence similarity 167, member A (FAM167A); its
conserved domain, DUF3259, is also of unknown function. Polymorphisms in the FAM167A-BLK
gene locus have been associated with several autoimmune diseases [298-300].

MMP1 and MMP10
Matrix metalloproteinase-1 and -10 (MMP1 and MMP10) are involved in the degradation of
the extracellular matrix [301]. MMP1 expression has been observed in other cancer types and
promotes tumor invasiveness [302]; overexpression has also been observed in endometrial cancer, but
the histological subtypes of the tumor samples studied were unclear [303]. Nevertheless, MMP1 was
stimulated by EGFR and HER2 signaling in ARK2 cells, and treatment of ARK1 and ARK2 cells
with the EGFR/HER2 inhibitor lapatinib downregulated MMP1 RNA and protein expression.
MMP10 expression is limited to epithelial cells in normal tissue [304] and targets collagen,
elastin and laminin [305]. MMP10 expression is a poor prognostic marker for ovarian cancer; in
addition, it is highly expressed in ovarian cancer stem-like cells and contributes to resistance to
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platinum-based chemotherapy [306]. Expression of MMP10 was also associated with increased
invasiveness of cervical cancer, and also promoted angiogenesis and suppressed apoptosis [307].

C11orf41
C11orf41 is a protein with unknown function, and is almost exclusively expressed in the
brain [308]. A novel PAX5-C11orf41 fusion transcript was found in one case of pediatric B-cell
precursor acute lymphoblastic leukemia [309], while a RUNX1-C11orf41 fusion transcript was
identified in a case of acute myeloid leukemia [310].

PPAPDC1A
Phosphatidic acid phosphatase type 2 domain containing protein 1A (PPAPDC1A) is from
the phosphatidic phosphatase family of proteins, which are involved in lipid metabolism and signal
transduction [311]. While PPAPDC1A is preferentially expressed in endothelial cells and testis [312],
its overexpression has been reported in ductal breast cancer [313]; however, its role in cancer
development has not been studied.

NKAIN1
Na,K-ATPase interacting 1 (NKAIN1) is a member of the NKAIN family of membrane
proteins, first identified as interacting partners of Na,K-ATPase [314], an enzyme that transports
sodium and potassium ions across the membrane to maintain an electrochemical gradient. This
regulation of ionic and osmotic homeostasis is required for normal cell function and cell survival
[315].
The NKAIN proteins are neuron-specific, while Na,K-ATPase is ubiquitously expressed
[316, 317]. However, the NKAIN proteins may promote proper functioning of Na,K-ATPase in the
brain: two patients with a truncated form of NKAIN2 have been reported to have severe neurological
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impairment [318, 319]. Overexpression of NKAIN2 has also been observed in more aggressive
neuroblastoma cell lines and high-risk tumor samples [320].
Apart from its role as an ion pump, Na,K-ATPase has also been shown to be involved in
protein scaffolding and signal transduction [321-323], affecting tumor cell proliferation, apoptosis,
adhesion and motility [324, 325]. Altered activity of Na,K-ATPase itself has been observed in various
tumor types and cancer cell lines, leading to interest in the anti-cancer properties of Na,K-ATPase
inhibitors [324, 326]. The most well-known class of Na,K-ATPase inhibitors are cardiac glycosides,
plant- and mammal-derived steroids that have long been used for the treatment of cardiac disease
[327, 328]. Taken together, this suggest that NKAIN1 may promote tumor aggressiveness of UPSC
through its effects on Na,K-ATPase function, and the use of Na,K-ATPase inhibitors may be of
clinical benefit.

GAL
Galanin (GAL) is a neuropeptide expressed in the brain and peripheral nervous system [329331] that modulates a broad range of physiological effects, such as nociception, memory, learning,
feeding, and hormone secretion [332, 333]. Its various physiological effects are mediated by the G
protein-coupled receptors GalR1, GalR2 and GalR3 [332], which have distinct downstream functions.
Both pro- and anti-tumor effects have been described: galanin upregulation in tumor and
serum has been reported in patients with colorectal cancer, where it is also a poor prognostic marker
[334]; in addition, expression is associated with increased invasiveness of colorectal cancer cells
[335]. On the other hand, expression of galanin, GALR1 and GALR2 have been linked to an antiproliferative, pro-apoptotic effect in neuroblastoma and oral carcinoma cell lines [336, 337]. Another
study found that while GALR1 was anti-proliferative, a net pro-proliferative effect was observed
when keratinocytes expressing all three receptors were stimulated with galanin, suggesting that the
receptors may have opposing effects [338].
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In endometrial cancer, GALR1 was identified as one of the most significantly
hypermethylated genes compared to normal endometrial tissue [339]. However, only 3 out of the 64
tumor samples were of serous histology.

SLCO4C1
The organic anion transporter family (OATP) is a group of plasma membrane transporters for
a wide range of organic compounds [340]. Solute carrier organic anion transporter family member
4C1 (SLCO4C1) was first characterized as a transporter of digoxin, a commonly prescribed drug for
heart failure [341]. SLCO4C1 is predominantly expressed in the kidney, and is involved in the
elimination of digoxin from the circulatory system. Other substrates include the drugs ouabain and
sitagliptin, thyroid hormones, cAMP, methotrexate and uremic toxins [341-343]. SLCO4C1
expression has also been detected in the brain and mammary gland, as well as in ovarian, breast and
lung cancer cell lines [344]. In addition, two SNPs associated with response to platinum-based
chemotherapy were also strongly associated with the expression of SLCO4C1 and SLC22A5,
suggesting that they may be involved in the transport of carboplatin in tumor cells [345, 346].

While we were able to discover potentially oncogenic genes using the TCGA data set, one
limitation was the lack of follow up data provided. At the time of download in May 2013, two follow
up files had been released; however, the median follow up times and number of deaths occurred were
both substantially less than in our own patient cohort (Table 9). The third and last follow up file that
has been released was in late 2013. An update to the follow up data would greatly increase the
statistical power of survival analyses and allow researchers to fully utilize the data.
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TCGA (pure UPSC)
n=91

IHC (mixed/pure)
n=74

1.51

8.88

0.81-2.22

2.77-14.98

Recurrences

11/24 (46%)

21/60 (35%)

Deaths

19/91 (21%)

43/74 (58%)

Median follow up (years)
95% CI

Table 9. Median follow up times and number of events in patient cohorts.
Median follow up times were calculated by reverse Kaplan-Meier analysis [258].

UCHL1 upregulation in UPSC

Based on our analysis with the TCGA data, we chose to study UCHL1 further for the
purposes of this dissertation, as UCHL1 had the highest median RSEM expression and one of the
highest fold change differences between UPSC and low-grade EEC among the 13 genes with nonnegligible expression. There was a marked upregulation of UCHL1 compared to all grades of EEC
and normal endometrial tissue. In addition, grade 3 EEC had an intermediate level of expression
between low-grade EEC and UPSC.
We also compared UCHL1 expression between the molecular clusters, as recently identified
by The Cancer Genome Atlas Research Network using integrated genomic data [72]. The copynumber high (serous-like) cluster of endometrial cancer samples had significantly higher UCHL1
expression compared to the other three clusters. This is to be expected, as the vast majority of UPSC
cases were in this cluster, which also included a quarter of all grade 3 EEC cases. Therefore, although
these molecular clusters may be useful in identifying high- and low-risk EEC patients, the clinical
utility for UPSC is limited. Further examination of UPSC patients alone to stratify patients into highand low- risk groups may have clinical benefit.

109

To validate our finding that UCHL1 was upregulated and associated with poorer clinical
outcome, we performed immunohistochemical staining of our own cohort of UPSC samples, which
confirmed that UCHL1 protein expression was significantly higher in UPSC than in EEC and preand post-menopausal normal endometrium. In normal endometrial tissues and the majority of EEC,
there was either no staining or cytoplasmic staining of UCHL1 near the apical surface of the
glandular cells. While the study by Kajimoto et al. reported lack of UCHL1 in most tissues,
expression in the uterus was not evaluated [116]. Although the expression level observed is low, the
role of UPSC in normal endometrium remains unknown.
Although UCHL1 was associated with poorer overall survival in the TCGA data set, we did not
find an association between UCHL1 expression and survival when analyzing early stage patients
alone or all patients together. However, in the 24 late stage UPSC patients (pure or mixed) with no
evidence of disease after completion of treatment, high UCHL1 expression was significantly
associated with poorer disease-free survival by univariate analysis, and overall survival by both
univariate analysis and multivariate analysis, suggesting that UCHL1 affects the clinical outcome of
late-stage UPSC patients rather than early-stage patients.
UCHL1 overexpression [128-132] and loss [120-127] has been reported in numerous cancer
types. Subsequently, there are conflicting reports that UCHL1 is a tumor suppressor [347] or
oncogene [136-139]. There are several possible reasons for the discrepancy between studies, even
within the same cancer type [106]. Firstly, reports of UCHL1 acting as a tumor suppressor has mostly
been inferred from in vitro studies and observed downregulation in patient samples, rather than by
survival analysis of patient data. One of the few studies that analyzed survival data found that UCHL1
promoter methylation was associated with poorer clinical survival in sporadic breast cancer patients,
but only by univariate analysis and not multivariate analysis [347].
Secondly, studies in different cancer types have reported several distinct downstream
signaling pathways, suggesting that UCHL1 has multiple possible target proteins and is contextspecific. For example, since UCHL1 has been reported to stabilize both wild-type p53 and various
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p53 mutants [124, 127, 143], the mutation status of TP53 may determine whether the net effects of
UCHL1 are tumor-suppressive or oncogenic. TP53 is mutated in the majority of UPSC; our five type
II cell lines were all TP53-mutant.
The specific tumor subtype studied may also determine the effect of UCHL1. For example,
Xiang et al. reported a loss of UCHL1 protein in a panel of breast cancer cell lines compared to
normal breast cells [143]. However, four out of nine cell lines retained UCHL1 expression at varying
levels: of these, BT-549 and MB-468 are triple negative, SK-BR3 is ER/PR negative, HER2 positive,
and YCC-B3 is of unknown receptor status [348, 349]. In addition, they observed promoter
methylation of UCHL1 in primary tumors; however, over half the cases had unknown hormone
receptor status, and the rest were split evenly between receptor-positive and receptor-negative. In
contrast, Lien et al. reported association of UCHL1 expression with the more aggressive triple
negative and basal-type breast cancers [350], suggesting that negative hormone receptor status is
associated with UCHL1 upregulation. UCHL1 has been associated with poorer survival in breast
cancer by both univariate analysis and multivariate analysis [139, 350]. Taken together, these studies
point to possibility that UCHL1 upregulation is an alternative to hormone signaling in the promotion
of tumorigenesis, and hence does not have a tumor-promoting effect in those that are hormonesensitive. Interestingly, UPSC shares molecular characteristics with triple negative and basal breast
cancers, such as frequent p53 mutation, negative hormone receptor status and HER2
amplification/overexpression. It remains to be seen if the effect of UCHL1 on endometrial cancer
progression is dependent on hormone status.
Lastly, the discrepancy between different studies may also be due to the stage of tumor
studied [106]. Reports of a tumor-suppressive function in prostate cancer used LNCaP cells taken
from the lymph node metastasis of an androgen-dependent tumor. In contrast, UCHL1 expression was
detected in the more aggressive, androgen-independent PC-3 and DU145 cell lines, which are taken
from bone metastasis and brain metastasis respectively [129, 142]. Again, it is possible that hormone
dependency determines the effect of UCHL1, but this will need to be studied further.
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Overall, it appears that UCHL1 is downregulated by hypermethylation in a subset of cancers,
as it may provide a tumor suppressive effect based on other signaling pathways involved. Conversely,
it is apparent that there is often a tumor-promoting effect, for example in hormone-negative breast,
prostate and endometrial cancer. This highlights the need to study the effects of UCHL1 in clearly
defined patient subpopulations that are relatively homogenous.

The functional role of UCHL1 in UPSC tumorigenesis

While differential expression of UCHL1 between serous and endometrioid endometrial
carcinomas has been previously reported in a microarray [351], and the function of this protein has
been studied in other cancers, the role of UCHL1 in endometrial cancer had not been explored in
depth. Although we did not observe changes in apoptosis, migration or invasion following UCHL1
silencing in vitro, there was a decrease in cell proliferation of ARK1 and ARK2 cells, suggesting that
UCHL1 promotes tumor cell proliferation. In contrast, there was no significant difference in cell
proliferation when the UCHL1-negative ACI-158 was transfected with anti-UCHL1 siRNA,
suggesting that the reduction in growth observed in ARK1 and ARK2 was not due to toxicity of the
siRNA.
We also observed a reduction in tumor growth in vivo with mice injected with ARK1-lucdox-shUCHL1 compared to ARK1-luc-dox-NT. Although this difference was significant, we
observed a large variation in our study utilizing ARK1 cells transduced with doxycycline-inducible
shRNA. One possible reason for this variation is errors in injection of the tumor cells. In one study
examining the errors of intraperitoneal injection in mice, the injection of radiological Ethiodol by five
experienced researchers was found in other organs instead of the peritoneal cavity in 21 of 150 mice
(14%) [352], most commonly in the stomach or small bowel. Other studies have reported a typical
failure rate of 10-20% [353], which could not be improved by procedure optimization such as varying
the needle size, angle of needle at penetration or injection into the right versus left lower abdominal
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quadrant [354]. Regardless, the lower right quadrant is preferred due to the stomach and cecum being
on the left side.
For our experiments, injections were on the right lower abdominal quadrant. With the second
in vivo experiment involving LDN-57444 treatment, extra care was taken to tilt the mouse slightly
with the head downwards, which may allow the stomach and bowels to move higher up the peritoneal
cavity and decrease chances of injection into those sites. This inherent failure rate also led us to
increase the number of mice used in the second in vivo experiment. We began with 50 mice for
intraperitoneal injection of ARK1 cells; two weeks later, we used the in vivo bioluminescence
intensities to exclude the 5 mice with the lowest bioluminescence. We then split the mice so that the
control and treatment group had a similar, mean, median and range of bioluminescent intensity.
Another possible reason for the large variation of tumor growth observed is the heterogeneity
of the ARK1 cell line during prolonged culture in vitro. We postulated that cancer cells taken from
the tumors successfully established in vivo may provide more consistent results in future experiments.
Therefore, using the mice in the control group (injected with ARK1-luc-dox-NT) that were moribund
at relatively early time points, we collected ascitic fluid immediately after sacrifice and plated it in
vitro to isolate the tumor cells. We were able to confirm successful isolation by treatment with
doxycycline, as red fluorescent protein was induced and detected with fluorescence microscopy. Cells
from the ascites of one mouse was then used for our second in vivo study involving LDN-57444
treatment.
Overall, with our modifications, we observed reduced variability of tumor growth in the
second in vivo study before we began treatment with LDN-57444 vs. control. With this experiment,
we observed a reduction in tumor growth and improved survival when mice with UPSC tumors were
treated with LDN-57444, indicating that inhibition of UCHL1 can reduce tumor burden and improve
overall survival.
LDN-57444 has previously been used in vivo in several studies, but to our knowledge LDN57444 treatment has not been administered over such a long period of time as in our experiment. For
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example, Goto et al. injected 0.5 mg/kg LDN-57444 intraperitoneally into nude mice for three
consecutive days before the mice were sacrificed a week later [139]. Although we found that LDN57444 could only be successfully dissolved in PBS with 0.5% DMSO and 2.5% ethanol, a thriceweekly injection of 0.5 mg/kg for 4 weeks did not lead to a noticeable drop in mouse body weight or
other visible adverse effects, suggesting that the treatment was well tolerated.
In spite of this, UCHL1 is abundant in the brain and peripheral nervous tissue; therefore,
potential side effects will need to be considered. The development of UCHL1 inhibitors with
increased specificity and tumor-specific delivery may increase the efficacy and lower the toxicity of
UCHL1-targeting drugs for clinical use.

Effect of UCHL1 on cyclin B1 protein stability

As a deubiquitinating enzyme from the family of ubiquitin carboxyl-terminal hydrolases
[112], UCHL1 has been shown to affect the protein stability of various cancer-related proteins. This
includes proteins related to cell cycle progression, such as p27 [112], p53 [124] and β-catenin [150].
However, when analyzing the RPPA data set from TCGA, we did not find any correlation between
UCHL1 mRNA expression and protein expression of p27, p53 or β-catenin. We also did not see a
change in p53 or β-catenin protein by western blot after UCHL1 silencing; the change in p27 levels
was not consistent across the two cell lines ARK1 and ARK2. Instead, we demonstrated for the first
time a significant correlation between UCHL1 and cyclin B1 protein expression, which was validated
by immunohistochemical staining of our own UPSC cohort.
Our in vitro studies demonstrated that UCHL1 silencing by siRNA reduced cyclin B1 protein
levels; the percentage of tumor cells positive for cyclin B1 was also lower in mice injected with
ARK1-luc-dox-shUCHL1 instead of ARK1-luc-dox-NT. Through immunoprecipitation studies, we
found that the decrease in cyclin B1 after UCHL1 silencing was due to an increase in ubiquitination.
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Our cycloheximide chase assay also showed that cyclin B1 protein half-life is shortened in UCHL1silenced cells.
UCHL1 has been shown to promote the kinase activity of CDK 1, 4 and 5, independent of its
deubiquitinating activity [147]. In addition, one previous study observed that UCHL1 interacted with
both cyclin B1 and CDK1 in Xenopus oocytes by immunoprecipitation [355]. In our study, we also
observed an interaction between cyclin B1 and UCHL1 by co-immunoprecipitation. To confirm this
finding, we performed the Duolink proximity ligation assay. Since cyclin B1 is predominantly
cytoplasmic during interphase, the red fluorescent spots were seen in the cytoplasm of the majority of
cells, indicating an interaction between UCHL1 and cyclin B1. However, when cells entered mitosis,
condensation of the chromosomes as seen by DAPI staining was accompanied by nuclear localization
of the red fluorescent spots, which persisted until anaphase when levels of cyclin B1 protein
decreased. As cyclin B1 begins its interaction with CDK1 as soon as it is expressed, UCHL1 is likely
interacting with the cyclin B1-CDK1 complex as a whole. Therefore, UCHL1 appears to interact with
cyclin B1-CDK1 throughout the cell cycle, regardless of cellular location, and is able to impair the
degradation of cyclin B1 by the APC at the metaphase-anaphase transition. The balance between
cyclin B1 ubiquitination by the APC and deubiquitination by UCHL1 could determine the degree and
rate of cyclin B1 degradation at the metaphase-anaphase transition, and also affect the basal level of
cyclin B1 observed in cells as they exit mitosis and enter interphase (Figure 34).
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Figure 34. Proposed model for the effect of UCHL1 on cyclin B1 ubiquitination and
degradation.

Dysregulation of cyclin B1 in cancer

Cyclin B1, complexed with CDK1, is the primary regulator of mitosis. As uncontrollable cell
proliferation is a hallmark of cancer [356], cyclin B1 overexpression has been observed in many
cancer cell lines and tumor samples [222-225]. For example, total/cytoplasmic cyclin B1 positivity
was associated with grade, mitosis and absence of estrogen/progesterone receptor in breast
carcinomas, while nuclear cyclin B1 was associated with poorer disease-free survival and overall
survival by multivariate analysis [226]. In an immunohistochemical study of EEC, cyclin B1 was
associated with increasing grade, stage, and poorer cancer-specific survival by univariate analysis
[229].
Previous studies suggest that uncontrolled mitosis is an early event in UPSC and contributes
to tumor development. Stage I UPSC samples had a significantly higher mitotic index than stage I,
low-grade EEC [357]. Using the TCGA data set, unsupervised clustering of RNA sequencing profiles
revealed that the majority of UPSC tumors were in the mitotic cluster, of which the most enriched
pathways were “mitotic roles of polo-like Kinase”, “G2/M DNA damage checkpoint regulation”, and
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“cell cycle control of chromosomal replication” by Ingenuity Pathway Analysis [72]. Cyclin B2 and
CDK1 were two of the four most upregulated genes. In addition, clustering based on integrated
analysis of exome sequencing, copy number alterations and microsatellite instability showed that the
majority of UPSC cases were in the copy-number high cluster, which had overexpression of cyclin
B1, CDK1 and cyclin E1 protein.
While cyclin E1 overexpression in UPSC is frequently due to its amplification, cyclin B1 is
not amplified or mutated in the UPSC samples of the TCGA data set, suggesting other mechanisms of
upregulation. In addition to mRNA upregulation and/or possible mRNA stabilization, our results
indicate that the frequent dysregulation of mitosis in UPSC is promoted by UCHL1 and its stabilizing
effect on cyclin B1. As we did not observe a significant difference in UCHL1 expression between
stages of UPSC in the RNA sequencing data from TCGA, or by immunohistochemical staining of our
own cohort of patient samples, this suggests that UCHL1 is overexpressed in UPSC early on in tumor
progression and can promote cyclin B1 protein stability, even when the tumor is confined to the
primary site. It is also possible that UCHL1 is an early event in UPSC pathogenesis that promotes
tumor development; however, this would require assessing UCHL1 levels in precursors to UPSC,
namely lesions of glandular dysplasia or intraepithelial carcinoma.

Effects of cyclin B1 on tumor progression

Defects in cyclin B1 degradation can affect cell cycle regulation and promote tumor
progression in several ways. Firstly, cyclin B1 overexpression shortens the cell cycle length [194,
230]. In our study, we observed slower progression of UCHL1-silenced ARK1 cells through the cell
cycle, which is in agreement with other studies.
Secondly, suppression of cyclin B1-CDK1 activity is essential for activation of the G2-M
checkpoint; therefore, cyclin B1 overexpression can allow cells to overcome the G2-M checkpoint
even when conditions have not been met to do so; i.e. DNA damage has not been repaired. This is
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further promoted when wild-type p53 function is lost, as transcription of cyclin B1 is negatively
regulated by p53 during induction of the G2-M checkpoint in response to cell stress and DNA
damage [231, 241]. As the vast majority of UPSC cases are TP53-mutant, this suppression does not
occur, which may further increase the ability of cells with extensive DNA damage to accumulate
cyclin B1 and overcome the G2-M checkpoint.
Thirdly, impaired cyclin B1 degradation at the metaphase-anaphase transition promotes
chromosomal instability by re-activating the spindle-assembly checkpoint, which in turn gives rise to
aneuploidy [358-360], a common feature of UPSC [43, 44, 361]. While cyclin B1 protein must
accumulate in order for cells to overcome the G2-M checkpoint, the opposite holds true for the
spindle-assembly checkpoint: rapid loss of cyclin B1 and CDK1 inactivation is required for cells to
overcome the checkpoint. In normal cells, this occurs at the metaphase-anaphase transition when the
sister chromatids are correctly aligned and attached to microtubules, resulting in activation of
APCCdc20 and rapid degradation of cyclin B1 [243, 255]. However, even with a slight retardation of
cyclin B1 degradation, cells can induce reactivation of the spindle checkpoint [362, 363]. As a result,
the cell fails to divide and undergoes mitotic arrest.
In normal tissue, cells that have undergone aberrant mitosis and have arrested undergo
mitotic catastrophe, where they are irreversibly committed to death or senescence [364]. However, a
fraction of these cells can gradually undergo mitotic slippage and escape mitotic arrest. This is due to
a gradual decrease in cyclin B1 until its levels are lower than the threshold needed to maintain the
checkpoint [365], or due to other compensatory mechanisms such as inactivation of CDK1 [366].
Slippage also occurs more easily in tumors if there are defects in spindle-assembly checkpoint
proteins [367].
As a result of mitotic slippage, tetraploid cells are able re-enter G1. Here, such cells can again
be detected and committed to G1 arrest or cell death. However, like the G2-M checkpoint, activation
of the G1 checkpoint in response to DNA damage also relies on functional p53, which is lost in the
majority of UPSC. Therefore, tetraploid cells are able to escape mitotic arrest, the G1 checkpoint and
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G2-M checkpoint. Tetraploid cells can in turn act as an unstable intermediate that eventually
generates aneuploid cells [368, 369].
Yin et al. previously reported that the oncogene c-Myc increased the transcription of cyclin
B1; the effect was enhanced when p53 was inactive [360]. In addition, constitutive cyclin B1
expression alone was sufficient to induce tetraploidy in a small fraction of myeloid cells after several
months of passage, and there was an additive effect when cyclin B1 overexpression was combined
with c-Myc overexpression. Similarly, we propose that the upregulation of UCHL1 in UPSC, coupled
with loss of p53 function, results in unscheduled cyclin B1 expression and/or impaired cyclin B1
degradation. Subsequently, UPSC tumors undergo increased cell cycle proliferation, and are able to
accumulate extensive chromosomal instability and aneuploidy without being directed to cell death or
senescence (Figure 35).

Figure 35. Proposed model of cyclin B1-mediated effects of UCHL1 on cell cycle progression in
TP53-mutant UPSC.
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Future directions

Cyclin B1 degradation kinetics
Although we showed that UCHL1 affects the ubiquitination and degradation of cyclin B1, it
remains to be seen whether UCHL1 promotes a slow but complete degradation of cyclin B1 at the end
of mitosis, or whether UCHL1 leads to increased basal levels of cyclin B1 carried over into
interphase. To determine the levels of cyclin B1 in interphase, one possible experiment would be to
perform multi-parameter flow cytometry: control and UCHL1-silenced cells would be labelled with
anti-cyclin B1 antibody, followed by a FITC-conjugated secondary antibody. DNA content would
also be labelled by staining with propidium iodide. Subsequently, flow cytometry analysis of these
samples would allow us to plot cyclin B1 expression against DNA content, which doubles from G1 to
mitosis [224].
The degradation of cyclin B in individual cells can also be monitored in vitro with expression
of the fusion protein cyclin B-SNAP [370, 371]. Endogenous cyclin B is silenced by shRNA, while
silent mutations are introduced into the cyclin B-SNAP sequence at the shRNA annealing site to
prevent its knockdown [371]. Addition of the SNAP-tag substrate during a labelling reaction allows
for fluorescent visualization of the cyclin B protein, whereby the drop in fluorescent intensity over
time reflects the rate of protein degradation [372, 373]. The addition of GFP-labelled histone H2
allows for the concurrent monitoring of chromosome alignment during mitosis.

The contribution of UCHL1 to pathogenesis
A mouse model of UCHL1 overexpression would be useful in studying the contribution of
UCHL1 to UPSC pathogenesis in vivo. A transgenic mouse overexpressing UCHL1 alone has
previously been described [132]; although UCHL1 expression in the endometrium was not reported,
UCHL1 expression was detected in most major organs. UCHL1-overexpressing mice exhibited an
increased rate of spontaneous tumors compared to wild-type mice at 16-18 months (70% vs. 16%),

120

with the majority of tumors being lymphomas or lung adenomas. In addition, UCHL1 overexpression
accelerated the development of lymphoma in Eμ-myc mice.
The presence of endometrial tumors was not reported, and it is unknown if any precursor
lesions were present. To determine whether UCHL1 overexpression alone is sufficient for the
development of UPSC, mice with overexpression of UCHL1 in the uterine epithelium could be
generated using the Cre-loxP model [374]. Similar to the SOX9 mouse model developed by Gonzalez
et al. [375], a mouse model with UCHL1 overexpression in the uterine epithelium may be developed
by first generating mice carrying a construct with a ubiquitous CAG promoter; a loxP-flanked RFPpolyA cassette that terminates transcription at its end; and a UCHL1 and EGFP cassette (CAGUCHL1 mice). Cre expression leads to DNA recombination at the loxP sites, removing the RFPpolyA cassette and allowing UCHL1 and EGFP expression. These mice can then be crossed with
mice carrying the progesterone receptor promoter (PGR-Cre) to generate PGR-Cre+/CAG-UCHL1+
male mice. Finally, these male mice would be crossed with homozygous CAG- UCHL1+/CAGUCHL1+ female mice to obtain PGR-Cre+/CAG-UCHL1+/CAG-UCHL1+ female mice with UCHL1
overexpression in the endometrium. If UCHL1 is indeed involved in tumorigenesis, UPSC tumors
should be observed at a higher frequency than in control mice.
Although the progesterone receptor promoter (PGR-Cre) has been used for the investigation
of endometrial hyperplasia and cancer [375-377], PGR is expressed in all the major cell types of the
uterus in the adult mouse, as well as in the ovary, oviduct, pituitary and mammary gland [378],
leading to interest in the use of alternative genes. An alternative promoter that may be used is
Lactoferrin-iCre, the activity of which is strongly detectable in the uterine epithelium of adult mice
but not the ovary and pituitary; in addition, Lactoferrin-iCre activity is only weakly detectable in
various other tissues [379]. Sprr2f-Cre activity is also specific to Müllerian epithelial cells of the
uterus, oviduct and cervix, as well as the urothelium of the bladder and uterer [380]. Sprr2f-Cremediated inactivation of LKB1 resulted in diffuse malignant transformation of the uterus and highly
invasive endometrial cancer in 100% of mice.
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If UCHL1 overexpression alone is insufficient to induce tumor development, it may be
combined with other genetic alterations, such as a TP53 deletion or a gain-of-function TP53 mutation,
as both are observed in UPSC. One study utilized Ksp1.3-Cre to generate mice with a kidney and
genitourinary tract-specific deletion of TP53 during embryogenesis (Ksp1.3-Cre/+;Trp53fl/fl mice).
Mice sacrificed at week 24-29 displayed regions of endometrial glandular dysplasia (EmGD), while
all mice sacrificed at week 47-58 displayed regions of EmGD and/or EIC. At 65-79 weeks, 16 of the
19 mice were found to have endometrial carcinomas, with frequent co-occurrence of tumors of
differing histology in one mouse. While the majority of tumors were of serous histology with or
without a clear cell component, several undifferentiated carcinomas and carcinosarcomas were also
observed. The combination of TP53 deletion or mutation and other genetic changes, such as
overexpression of HER2, cyclin E1 or p16, may also accelerate UPSC development.
UPSC tends to arise in postmenopausal women with atrophic or resting endometrium, and are
typically estrogen and/or progesterone receptor-negative [34]. Although mice do not undergo
menopause, reproductive senescence and loss of cyclic activity has been reported to occur in
C57BL/6J mice at approximately 11-16 months of age [381], leading to a reduction in estradiol levels
[382], albeit not as drastically as in postmenopausal women. It is unknown whether genetic changes
that initiate UPSC require a long period of time to develop or are inhibited by a premenopausal
environment; nevertheless, it is possible that the induction of menopause in future mouse models may
accelerate the development of UPSC. The industrial chemical 4-vinylcyclohexene diepoxide (VCD)
has been shown to induce gradual menopause in mice by accelerating degeneration of the primordial
and primary ovarian follicles. Administration of VCD in 28 day-old B6C3F1 mice by 20 consecutive
days of intraperitoneal injection resulted in ovarian failure at a mean of 52 days after onset of dosing
[383]. Plasma levels of follicle-stimulating hormone (FSH) were also significantly increased
compared to control mice at a mean of 35 days after onset of dosing, due to loss of 17β-estradiol and
progesterone secretion by the ovarian follicles [384, 385].
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The contribution of UCHL1 to aneuploidy
It is unknown whether UCHL1 overexpression precedes the development of aneuploidy in
UPSC. To our knowledge, only one study has measured the presence of aneuploidy in precursor
lesions. In this study of concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian
carcinoma in nine patients, six of the EIC lesions displayed some degree of aneuploidy as determined
by in situ DNA ploidy analysis [386]. It remains to be seen whether aneuploidy is also present in the
less malignant endometrial glandular dysplasia (EmGD). As both precursor lesions have been
frequently observed in patients with concurrent UPSC (53% for EmGD [387]; 89% for EIC [38]), the
expression of UCHL1 by immunohistochemical analysis of all three lesions from the same patient,
along with DNA ploidy analysis by in situ image cytometry [388, 389], would allow us to determine
whether UCHL1 overexpression is frequently detected before the development of aneuploidy.
To establish whether UCHL1 induces aneuploidy, a potential in vitro experiment, similar to
the study by Yin et al. [360], would be to generate UCHL1-overexpressing and cyclin B1overexpressing stable clones of UCHL1-negative endometrial cancer cell lines, and observe changes
in DNA ploidy over a prolonged period of cell culture. Tetraploidy may also be induced shortly after
generation of stable clones by treatment with the mitotic spindle inhibitor, Nocodazole [360, 390]. To
determine whether loss of wild-type p53 is also required for the generation of aneuploidy, stable
UCHL1 expression could also be combined with the reintroduction or loss of wild-type TP53.
To study the contribution of UCHL1 to aneuploidy development in vivo, a mouse model of
UPSC, such as mice with endometrium-specific TP53 deletion or mutation, with and without UCHL1
overexpression, can be used to study the contribution of UCHL1 to aneuploidy development and
tumor initiation. If UCHL1 contributes to aneuploidy, we would expect an increase in the degree of
aneuploidy in the tumors of mice with UCHL1 overexpression.
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Translational significance of study

The rarity of UPSC has been a constant challenge in the development of novel targeted
therapies. The collection of a relatively large cohort of UPSC cases from multiple institutions in the
TCGA data sets allowed us to discover novel therapeutic targets with sufficient statistical power. We
subsequently found UCHL1 RNA expression to be upregulated in UPSC compared to the more
benign low-grade endometrioid endometrial carcinoma and normal endometrial tissue. In addition, we
were able to validate our findings by immunohistochemical staining of our own smaller patient
cohort, where high UCHL1 expression was associated with disease-free and overall survival in latestage patients with no evidence of disease after treatment. As over 50% of patients with UPSC are
diagnosed at a late stage, this suggests that targeting UCHL1 could be of benefit to a large subset of
UPSC patients.
Our studies showed that UCHL1 promoted cell cycle progression both in vitro and in vivo;
treatment of UPSC-bearing mice with the UCHL1-specific inhibitor LDN-57444 also reduced tumor
growth and increased overall survival times. Subsequently, we demonstrated that the effect of
UCHL1 on tumor growth was due to its ability to impair the ubiquitination and degradation of cyclin
B1, an essential protein in mitotic progression.
As mitotic dysregulation was frequently seen in the serous-like cluster as described by the
TCGA network [72], our results provides insight into how this possibly occurs. The frequent loss of
p53 in UPSC, coupled with UCHL1 overexpression, promotes the stabilization of cyclin B1 and the
propagation of tumor cells with extensive chromosomal stability. This suggests that UCHL1 has a
role in the increased aggressiveness of UPSC compared to other endometrial cancer subtypes, due to
its contribution to cyclin B1 dysregulation.
Targeting the ubiquitin-proteasome system as an anti-cancer strategy has been gaining
interest. Inhibitors of the 20S catalytic subunit of the proteasome, bortezomib and carfilzomib, are
FDA-approved for the treatment of hematological malignancies [391, 392]. However, toxicity and
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drug resistance to bortezomib is observed in patients with multiple myeloma after prolonged
treatment [393-395]. In addition, bortezomib and carfilzomib are administered systemically, and the
efficacy of bortezomib for the treatment of solid tumors has been disappointing [396]. The secondgeneration proteasome inhibitor MLN2238 is orally bioavailable and has demonstrated anti-cancer
effect in breast cancer [396]. Nevertheless, inhibitors that target specific components of the ubiquitinproteasome system upstream from the 26S proteasome, such as the deubiquitinating enzymes
(DUBs), should improve toxicity profiles [397].
Apart from UCHL1, other DUBs such as UCHL5, USP4, USP6, USP7, USP8, USP14 and
USP28 have cancer-promoting functions [398]. While DUBs are promising therapeutic targets, no
DUB inhibitors have been FDA-approved so far [399-401]. VLX1570, an inhibitor of USP14 and
UCHL5, is currently being evaluated in a phase I/II trial for patients with relapsed/refractory multiple
myeloma (NCT02372240 [402]). Drugs approved for other diseases have also shown anti-cancer
potential due to their DUB-inhibitory activity. Pimozide, an anti-psychotic drug, has been found to
inhibit USP1 [403], while auranofin, a gold-containing compound approved for the treatment of
rheumatic arthritis, has emerged as an inhibitor of USP14 and UCHL5 [404]. Although several
compounds, including LDN-57444 [261, 405, 406], have been identified as UCHL1 inhibitors, their
role is currently restricted as research tools. MISSION Therapeutics are in the process of developing
specific DUB inhibitors with oral bioavailability, including one or more that specifically targets
UCHL1 [401, 407].
In addition to targeting UCHL1 activity, inhibition of cell cycle proteins may also be
beneficial in the management of UPSC. For over 20 years, there has been interest in the development
of CDK inhibitors as an anti-cancer strategy. The first generation of drugs consisted of “pan-CDK”
inhibitors that affected multiple CDK proteins with limited success in clinical trials. For example, the
plant-derived flavopiridol was the first CDK inhibitor to be evaluated in clinical trials [408, 409];
treatment has shown clinical benefit for certain hematological malignancies [410-413], but the same
efficacy could not be observed in solid tumors [414-416]. Other first-generation inhibitors have
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similarly shown limited success in solid tumors, due to lack of bioavailability and toxicity issues from
the lack of CDK specificity [415, 417, 418].
Second-generation inhibitors were subsequently developed with the aim of improved
specificity, with much of the focus being on CDK4 and CDK6, which together with cyclin D1
promote G1-S transition. Palbociclib is a small-molecule CDK4/6 inhibitor that prevents downstream
phosphorylation of functional Rb and blocks G1-S transition [419, 420]. A phase II trial found
significantly improved progression-free survival when postmenopausal women with estrogen
receptor-positive, HER2-negative metastatic breast cancer were treated with palbociclib plus letrozole
versus letrozole alone (20.2 months versus 10.2 months) (PALOMA-1/TRIO-18 [421]); therefore, its
use in combination with letrozole has been approved for first-line treatment of this patient population
[422].
Development of inhibitors against the other CDK proteins is ongoing. CYC065 is an orally
available, second-generation CDK2/9 inhibitor that interferes with cyclin E1-CDK2 activity, resulting
in anaphase catastrophe [423]. Cyclin E1 amplification/overexpression has been proposed as a
mechanism of resistance to the anti-HER2 antibody trastuzumab in HER2-amplified breast cancer;
CYC065 treatment of mice with xenografts derived from CCNE1-amplified, trastuzumab-resistant
breast cancer cells led to a significant reduction in tumor growth [424]. In addition, CYC065 inhibited
tumor growth of CCNE1-amplified UPSC cell lines in vitro and cell line-derived xenografts in vivo;
combination treatment of CYC065 with the PIK3CA inhibitor taselisib showed a synergistic effect
[425]. The use of CYC065 is currently being evaluated in a phase I clinical trial for patients with
advanced cancer (NCT02552953 [426]).
8-hydroxypiperidine-methyl-baicalein (BA-j) has recently been designed and synthesized as a
flavonoid derivative with improved bioavailability compared to the parent compound baicalein and
other flavonoids, either injected or orally administered. BA-j was demonstrated to have selective
CDK1 inhibitory activity and only weak activity against CDK2/4/6. BA-j treatment of MCF-7 and
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HL-60 cells led to G1 and G2 arrest and a dose-dependent increase in apoptosis [427, 428], indicating
potential as an anti-cancer drug.
In summary, we have established that UCHL1 is a novel prognostic marker for UPSC and a
viable therapeutic target. Further development of UCHL1 and CDK1 inhibitors would potentially
benefit this understudied population of patients with aggressive disease.
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